zoledronic acid has been researched along with Kahler Disease in 272 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (1.47) | 18.2507 |
| 2000's | 118 (43.38) | 29.6817 |
| 2010's | 130 (47.79) | 24.3611 |
| 2020's | 20 (7.35) | 2.80 |
| Authors | Studies |
|---|---|
| Berghuis, AM; De Schutter, JW; Huang, XF; Lin, YS; Park, J; Sebag, M; Tsantrizos, YS | 1 |
| Berghuis, AM; Gómez Palou, M; Huang, XF; Lacbay, CM; Park, J; Sebag, M; Ta, V; Tsantrizos, YS; Vincent, F; Waller, DD | 1 |
| Andoh, K; Burdalski, C; Burton, B; Gilmore, S; Goldenhorn, M; Porter, T; Proctor, C; Sproat, MR | 1 |
| Berns, JS; Geara, AS; Shulman, R | 1 |
| Fasciolo, A; Fusco, V; Gambino, A; Palmeri, S; Rossi, M | 1 |
| Chatziravdeli, V; Doxani, C; Katsaras, D; Katsaras, GN; Stefanidis, I; Zintzaras, E | 1 |
| Avonto, I; Castella, B; D'Agostino, M; Giannotta, C; Grasso, M; Grimaldi, D; Kopecka, J; Larocca, A; Massaia, M; Riganti, C; Tripoli, E | 1 |
| Abe, M; Harada, T; Hiasa, M; Miki, H; Nakamura, S; Teramachi, J | 1 |
| Hong, BM; Hong, WW; Kim, IH; Mupparapu, M; Oak, S | 1 |
| Baek, YH; Hong, S; Jeon, HL; Oh, IS; Park, J; Shin, JY; Yang, H | 1 |
| Karpiłowska, A; Podgórska, J; Popow, M; Radziszewski, M; Ziółkowska, A | 1 |
| Álvarez-Yagüe, E; Junquera, L; Junquera, S; Rúa, L; Ugalde, R | 1 |
| Caruso, SR; Covas, DT; de Macedo, LD; De Santis, GC; Fernandes, TR; Ferrari, TC; Innocentini, LMAR; Orellana, MD; Ricz, HMA | 1 |
| Ehresman, J; Khan, M; Luna, LP; Sankaran, N; Sciubba, DM | 1 |
| Chang, CS; Chng, WJ; Gao, S; Glennane, A; Gordon, SW; Huang, SY; Min, CK; Shimizu, K; Wang, Y; Wong, RS; Yoon, SS | 1 |
| Chen, C; Cui, Y; Li, M; Li, R; Ma, L; Yang, T; Zhou, S; Zhou, Y | 1 |
| Ntanasis-Stathopoulos, I; Terpos, E | 1 |
| Canon, J; Croucher, P; Garcia-Sanz, R; Glennane, A; Leleu, X; Pasteiner, W; Pawlyn, C; Raje, N; Terpos, E; Wang, Y | 1 |
| Billias, C; Langer, M; Schorr, R; Ursu, S | 1 |
| Buda, G; Carulli, G; Dalla Palma, B; Fazzi, R; Galimberti, S; Giuliani, N; Morganti, R; Notarfranchi, L; Petrini, I | 1 |
| Cui, X; Jiang, L; Ma, H; Tang, X | 1 |
| Kanri, Y; Kobayashi, E; Minami, Y; Ogawa, R; Ogura, I; Okada, Y; Ono, J; Tanaka, A | 1 |
| Abi-Hanna, D; Baldock, PA; Bassett, JHD; Cheng, TL; Croucher, PI; Fairfield, H; Falank, C; Ghobrial, IM; Hose, D; Kneissel, M; Kramer, I; Le, LMT; Little, DG; McDonald, MM; Mohanty, ST; Morse, A; Oyajobi, BO; Pettitt, JA; Phan, TG; Reagan, MR; Seckinger, A; Simic, MK; Terry, RL; Vanderkerken, K; Williams, GR; Youlten, SE | 1 |
| Bagratuni, T; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kastritis, E; Melakopoulos, I; Melea, P; Migkou, M; Roussou, M; Terpos, E | 1 |
| Davies, M; Kanatas, A; Power, A | 1 |
| Raje, NS; Yee, AJ | 1 |
| Djulbegovic, B; Kumar, A; Mhaskar, R; Miladinovic, B | 1 |
| Amler, E; Amodio, N; Caraglia, M; Di Martino, MT; Grimaldi, A; Misso, G; Russo, M; Tagliaferri, P; Tassone, P; Zappavigna, S; Zarone, MR | 1 |
| Cheng, P; Durie, B; García-Sanz, R; Krejčí, M; Laribi, K; Legieć, W; Raje, N; Roodman, GD; Shimizu, K; Terpos, E; Warner, D; Willenbacher, W; Zhu, L | 1 |
| Dimopoulos, MA; Kastritis, E | 1 |
| García-Sanz, R; Hechmati, G; Intorcia, M; Kennedy, L; Raje, N; Roodman, GD; Sabatelli, L; Shimizu, K; Terpos, E; Willenbacher, W | 1 |
| Allegra, A; Allegra, AG; Avenoso, A; Campo, S; D'Ascola, A; Innao, V; Mania, M; Musolino, C; Oteri, G | 1 |
| Bell, SE; Cairns, DA; Child, JA; Cook, G; Davies, FE; Drayson, MT; Gregory, WM; Jackson, GH; Morgan, GJ; Owen, RG; Royle, KL | 1 |
| Kalin-Hajdu, E; Martin, TG; Narayan, R; Tan, M; Wong, SW | 1 |
| Almaden, WF; Chen, Y; Gong, Y; Kashtwari, D; Katz, J; Moreb, J; Wazzan, T | 1 |
| Dimopoulos, MA; Gavriatopoulou, M; Kanellias, N; Terpos, E | 1 |
| Chantry, AD; Down, JM; Evans, H; Green, AC; Lath, D; Lawson, MA; Paton-Hough, J; Snowden, JA; Tazzyman, S | 1 |
| Djulbegovic, B; Mhaskar, R | 1 |
| Bolzoni, M; Ferretti, M; Giuliani, N; Palumbo, C; Toscani, D | 1 |
| Accordino, MK; Bhutani, D; Chen, Y; Hershman, DL; Hillyer, GC; Leng, S; Lentzsch, S; Lim, E; Neugut, AI; Tsai, WY; Wright, JD | 1 |
| Bhowmik, D; Campioni, M; Christodoulopoulou, A; Jamotte, A; Kennedy, L; Terpos, E; Willenbacher, W | 1 |
| Dimopoulos, MA; Kleber, M; Ntanasis-Stathopoulos, I; Terpos, E | 1 |
| Delaissé, JM; Hansen, CT; Jakobsen, EH; Jørgensen, HB; Plesner, T; Søe, K | 1 |
| Cavo, M; Dimopoulos, MA; Drake, MT; Durie, BG; García-Sanz, R; Jurczyszyn, A; Leleu, X; Lentzsch, S; Merlini, G; Morgan, G; Munshi, N; Raje, N; Rajkumar, SV; Reiman, T; Roodman, GD; Sezer, O; Shimizu, K; Spencer, A; Terpos, E; Turesson, I | 1 |
| Blanquer, M; Gonzálvez-García, M; Moraleda, JM; Oñate-Sánchez, R; Rodríguez-González, MA; Rodríguez-Lozano, FJ; Segarra-Fenoll, D; Villanueva, V | 1 |
| Cho, SH; Chul-Hyun, L; Go, BS; Kim, SW; Kim, WC | 1 |
| Delabaye, I; Delforge, M; Doyen, C; Duck, L; Van den Wyngaert, T; Wildiers, H; Wouters, C; Wouters, K | 1 |
| Boccadoro, M; Brioli, A; Child, JA; Cook, G; Davies, FE; Drayson, MT; Gregory, WM; Jackson, GH; Larocca, A; Morgan, GJ; Owen, RG; Palumbo, A; Russell, N; Szubert, A; Wu, P | 1 |
| Soydan, SS; Uckan, S | 1 |
| Arra, C; Bruzzese, F; Budillon, A; Caraglia, M; Chianese, MI; Ciardiello, C; Di Gennaro, E; Franco, R; Leone, A; Luciano, A; Milone, MR; Pucci, B; Rocco, M; Santini, D | 1 |
| Body, JJ | 3 |
| Costa, L; Dansey, R; Feng, A; Henry, D; Hirsh, V; Hungria, V; Jun, S; Scagliotti, G; Smith, G; Vadhan-Raj, S; von Moos, R; Woll, PJ; Yeh, H | 1 |
| Delaissé, JM; Hansen, CT; Jakobsen, EH; Plesner, T; Søe, K | 1 |
| Brown, J; Fullarton, JR; Palmieri, C | 1 |
| Bokhari, SW; Jones, FM | 1 |
| Alegre, A; Bailén, A; Giraldo, P; Gironella, M | 1 |
| Berk, V; Cetin, M; Elmali, F; Enhos, S; Eser, B; Inanc, M; Karaca, H; Kaynar, L; Ozkan, M; Pala, C; Sıvgın, S | 1 |
| Ashcroft, AJ; Bell, SE; Boyd, KD; Byrne, J; Child, JA; Cook, G; Davies, FE; Drayson, MT; Feyler, S; Gregory, WM; Jackson, GH; Morgan, GJ; Navarro Coy, N; Osborne, WL; Owen, RG; Roddie, H; Ross, FM; Rudin, C; Szubert, AJ; Wu, P | 1 |
| Mizuki, M; Morio, K; Tsugane, M; Uejima, E | 1 |
| Carson, K; Colditz, G; Gage, B; Luo, S; Sanfilippo, KM; Tomasson, M; Vij, R; Weilbaecher, K | 1 |
| Anderson, KC; Bianchi, G; Richardson, PG | 1 |
| Anderson, KC; Ghobrial, IM; Laubach, JP; Munshi, NC; Nemani, N; Patel, CG; Raje, NS; Richardson, PG; Santo, L; Schlossman, RL; Scullen, TA; Yee, AJ | 1 |
| Beck, JT; Bilic, S; Isaacs, R; Iyer, SP; Kelly, KR; Munshi, NC; Sen, S; Shah, J; Stewart, AK | 1 |
| Felsenberg, D; Gabbert, TI; Hoffmeister, B | 1 |
| Jaiswal, S; Noriega Aldave, AP | 1 |
| Gamie, Z; Kenanidis, E; Kostakos, T; Kyrkos, J; Papamerkouriou, YM; Papavasiliou, K; Potoupnis, M; Sarris, I; Tsiridis, E | 1 |
| Hashimoto, A; Horiguchi, H; Ibata, S; Iyama, S; Kamihara, Y; Kato, J; Kobune, M; Ono, K; Sato, T; Takada, K; Takimoto, R; Tatekoshi, A | 1 |
| Fan, KH; Hou, J; Hu, XY; Huang, Q; Ma, J; Ren, JD; Tan, Y; Wu, J; Xiao, JR; Xiao, WJ; Zheng, W | 1 |
| Chantry, AD; Evans, HR; Harris, W; Lawson, MA; Paton-Hough, JM; Ratnabalan, D; Snowden, JA; Walker, RE | 1 |
| Body, JJ; Braun, A; Diel, IJ; Feng, A; Goldwasser, F; Spencer, A; Steger, G; Stopeck, AT; Vadhan-Raj, S; von Moos, R | 1 |
| Abe, H; Ashihara, E; Hirai, H; Kanai, M; Kimura, S; Maekawa, T; Miida, T; Munaka, T; Nakagawa, S; Nakagawa, Y; Shoji, S; Yamato, S | 1 |
| Abellá, E; Bargay, J; Blanchard, MJ; de la Rubia, J; García-Sanz, R; Gironella, M; Granell, M; Hernández, MT; Mateos, MV; Moreno, MJ; Ocio, EM; Oriol, A; Palomera, L; Payer, AR; Ribas, P; Ribera, JM; San Miguel, JF; Teruel, AI | 1 |
| Abe, M; Miki, H; Nakamura, S | 1 |
| Agarwal, A; Aung, TT; Strand, AO | 1 |
| Anderson, KC; Argonza-Aviles, E; Badros, A; Ericson, SG; Hadala, JT; Montgomery, CW; Munshi, N; Orlowski, R; Raje, N; Vescio, R; Warsi, G | 1 |
| Alexeeva, Y; Balakumaran, A; Braun, A; Facon, T; Feng, A; Hungria, V; Raje, N; Roodman, GD; Spencer, A; Stewart, AK; Terpos, E; Vadhan-Raj, S; Willenbacher, W | 1 |
| Ding, K; Ding, S; Fu, R; Guan, J; Li, L; Liu, H; Liu, Z; Peng, F; Qu, W; Ruan, E; Shao, Z; Song, J; Wang, G; Wang, H; Wang, X; Wang, Y; Wu, Y; Xing, L | 1 |
| Mohamed, M | 1 |
| De Angelis, G; Ferretti, A; Petrucci, MT | 1 |
| Bonanini, M; Fornaini, C; Giovannacci, I; Manfredi, M; Meleti, M; Merigo, E; Vescovi, P | 1 |
| Abe, M; Aihara, K; Amachi, R; Bat-Erdene, A; Cui, Q; Endo, I; Fujii, S; Harada, T; Iwasa, M; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Oda, A; Ozaki, S; Sogabe, K; Teramachi, J; Yoshida, S | 1 |
| Foster, JC; Go, RS; Grubbs, SS; Himelstein, AL; Khatcheressian, JL; Loprinzi, CL; Novotny, PJ; O'Connor, T; O'Mara, A; Qin, R; Roberts, JD; Seisler, DK; Shapiro, CL; Velasco, MR; Weckstein, D | 1 |
| Fu, R; Gao, S; Jiang, F; Li, L; Liu, H; Liu, Z; Peng, F; Ruan, E; Shao, Z; Song, J; Wang, G | 1 |
| Avilès, A; Cleto, S; Huerta-Guzmàn, J; Nambo, MJ; Neri, N | 1 |
| Gallego, L; Junquera, L | 1 |
| Andriani, A; Balleari, E; Boccadoro, M; Bongarzoni, V; Bringhen, S; Caravita, T; D'Arena, G; Guglielmelli, T; Musto, P; Palumbo, A; Petrucci, MT; Pietrantuono, G | 1 |
| Bamia, C; Bamias, A; Christoulas, D; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Gika, D; Kastritis, E; Melakopoulos, I; Migkou, M; Roussou, M; Terpos, E | 1 |
| Chen, Q; Dong, M; Feng, FY; Feng, JF; Jiao, SC; Li, J; Liu, JW; Ren, J; Song, ST; Wang, XW; Wang, YJ; Wang, ZH; Xie, GR; Xu, N; Zhang, Y; Zhou, QH | 1 |
| Gallego, L; Junquera, L; Villarreal, P | 1 |
| Abildgaard, N; Gregersen, H; Lund, T; Marker, P; Vangsted, A | 1 |
| Almojaly, SA; Berk, J; Dziak, R; Goodloe Iii, S; Margarone Iii, J; Rao, MV; Sullivan, M | 1 |
| Grasko, JM; Herrmann, RP; Vasikaran, SD | 1 |
| Khan, AM; Sindwani, R | 1 |
| Aki, SZ; Cetiner, M; Cetiner, S; Gultekin, SE; Haznedar, R; Kahraman, SA; Kocakahyaoglu, B; Sucak, GT | 1 |
| Abe, Y; Goto, S; Kaneko, T; Muto, M; Nakagawa, Y; Nicol, A; Nieda, M; Suzuki, K; Yokokawa, K | 1 |
| Bakker, F; Baum, W; Burger, R; Gordon, S; Gramatzki, M; Green, JR; Guenther, A; Roelofs, AJ; Rogers, MJ; Tiemann, M | 1 |
| Ando, R; Fukami, K; Hashiguchi, M; Hazama, T; Koike, K; Morishige, S; Nagano, M; Nishida, H; Okuda, S; Taguchi, K; Tamaki, K; Ueda, S; Yoshimura, J | 1 |
| Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K | 1 |
| Crawford, BS; Kraut, EH; McNulty, RM; Turowski, RC | 1 |
| D'Auria, F; Dammacco, F; Di Pietro, G; Ditonno, P; Gnoni, A; Guarini, A; Mangialardi, G; Moschetta, M; Musto, P; Ria, R; Ribatti, D; Ricciardi, MR; Vacca, A | 1 |
| Ameratunga, R; Chiu, W; Oei, P; Pullon, H; The, R; Woon, ST | 1 |
| Bernardeschi, P; D'Alessandro, M; Del Conte, A; Fiorentini, G; La Ferla, F; Montagnani, F; Turrisi, G | 1 |
| Berenson, J; Coleman, RE; Cook, RJ; Lipton, A; Terpos, E | 1 |
| Anargyrou, K; Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Kokkoris, P; Migkou, M; Terpos, E; Tsionos, K | 1 |
| Abildgaard, N; Delaisse, JM; Lund, T; Plesner, T | 1 |
| Berenson, JR | 7 |
| Hohl, RJ; Holstein, SA | 1 |
| Altundag, K; Ararat, E; Ozdemir, E; Sahin, I | 1 |
| Abeltino, M; Agnelli, L; Bolzoni, M; Bonomini, S; Colla, S; Giuliani, N; Neri, A; Rizzoli, V; Storti, P; Todoerti, K | 1 |
| Berenson, JR; Bolejack, V; Crowley, J; Farber, CM; Flinn, IW; Gravenor, DS; Hilger, JD; Makary, A; Morganstein, N; Nassir, Y; Sanani, S; Sefaradi, A; Shamouelian, A; Staszewski, H; Swift, RA; Tiffany, NM; Upadhyaya, GH; Yang, HH; Yellin, O | 1 |
| Ashcroft, AJ; Bell, SE; Byrne, J; Child, JA; Cocks, K; Cook, G; Davies, FE; Drayson, MT; Feyler, S; Gregory, WM; Jackson, GH; Morgan, GJ; Navarro-Coy, N; Owen, RG; Roddie, H; Ross, F; Rudin, C; Szubert, AJ | 1 |
| Rajkumar, SV | 2 |
| Brandi, ML; Cavalli, L; Cavalli, T; Falchetti, A; Marini, F; Masi, L; Tonelli, P | 1 |
| Nathan, C; Phillips, JM; Thibodeaux, JD | 1 |
| Arduino, PG; Battaglio, C; Berardi, D; Broccoletti, R; Chiecchio, A; Donadio, M; Gandolfo, S; Menegatti, E; Mozzati, M; Scoletta, M; Scully, C; Vandone, AM | 1 |
| Gnanapandithan, K; Kumar, S; Malhotra, P; Sharma, A; Singh, S; Varma, S | 1 |
| Costa, L; Dansey, R; Goldwasser, F; Henry, DH; Hirsh, V; Hungria, V; Jiang, Q; Jun, S; Prausova, J; Scagliotti, GV; Sleeboom, H; Spencer, A; Vadhan-Raj, S; von Moos, R; Wang, J; Willenbacher, W; Woll, PJ; Yeh, H | 1 |
| Terpos, E | 1 |
| Berenson, J; Dimopoulos, MA; Terpos, E | 1 |
| Morgan, GJ | 2 |
| Green, JR; Guenther, A | 1 |
| Fukami, K; Koike, K; Morishige, S; Okamura, T; Okuda, S; Taguchi, K; Yakushiji, K | 1 |
| Burkley, B; Casanova, O; Ferreira, P; Gong, Y; Hou, W; Katz, J; Langaee, TY; Moreb, JS; Salmasinia, D | 1 |
| Abbruzzese, A; Ascani, R; Calimeri, T; Caraglia, M; Cigliana, G; De Rosa, G; Franco, R; La Rotonda, MI; Leonetti, C; Liguori, G; Marra, M; Salzano, G; Scarsella, M; Tagliaferri, P; Tassone, P; Zappavigna, S | 1 |
| Pozzi, S; Raje, N | 1 |
| Ludwig, H; Zojer, N | 1 |
| Arbitrio, M; Baudi, F; Calimeri, T; Cannataro, M; Cucinotto, I; Di Martino, MT; Guzzi, PH; Leone, E; Piro, E; Prantera, T; Rossi, M; Tagliaferri, P; Tassone, P; Veltri, P | 1 |
| Lockhart, AC; Sorscher, SM | 1 |
| Abe, M; Amou, H; Cui, Q; Fujii, S; Harada, T; Hiasa, M; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Oda, A; Ozaki, S; Shibata, H; Takeuchi, K; Watanabe, K; Yata, K | 1 |
| Bensimon, AG; Ericson, SG; Guo, A; Marynchenko, M; Namjoshi, M; Raje, N; Wu, EQ; Yu, AP | 1 |
| Kyrgidis, A; Tzellos, TG | 1 |
| Kami, M; Matayoshi, T; Takeuchi, K; Tanimoto, T; Yagasaki, F | 1 |
| Boccadoro, M; Bosia, A; Canepari, ME; Castella, B; Coscia, M; Fiore, F; Foglietta, M; Massaia, M; Palumbo, A; Pantaleoni, F; Peola, S; Riganti, C | 1 |
| Ashcroft, AJ; Bell, SE; Byrne, J; Child, JA; Cocks, K; Cook, G; Davies, FE; Drayson, MT; Feyler, S; Gregory, WM; Jackson, GH; Morgan, GJ; Navarro-Coy, N; Owen, RG; Roddie, H; Ross, FM; Rudin, C; Szubert, AJ; Wu, P | 1 |
| Dimopoulos, MA; Terpos, E | 1 |
| Lipton, A | 1 |
| Jacobs, I; Lipton, A | 1 |
| Curi, MM; Lascala, CA; Marques, MM; Martins, MA; Martins, MD; Migliorati, CA; Tenis, CA | 1 |
| Hewson, ID | 1 |
| Anderson, KC; Ghobrial, IM; Laubach, JP; Mahindra, A; Mitsiades, CS; Munshi, N; Raje, N; Richardson, PG; Rosenblatt, J; Schlossman, RL | 1 |
| Adamo, D; Aria, M; Fortuna, G; Leuci, S; Mignogna, MD; Orabona, GD; Pollio, A; Ruoppo, E | 1 |
| Chen, Y; Kim, K; Kim, YK; Pai, VR; Srivastava, A; Suh, C; Teoh, G; Yoon, SS | 1 |
| Bains, M; Chandiwana, D; Delea, TE; El Ouagari, K; Kaura, S; Morgan, GJ; Rotter, J; Taylor, M | 1 |
| De Stefano, V; Logroscino, CA; Proietti, L; Scaramuzzo, L; Tamburrelli, FC | 1 |
| Iida, S | 1 |
| Henk, HJ; Kaura, S; Perez, JR; Teitelbaum, A | 1 |
| Ashcroft, AJ; Bell, SE; Child, JA; Davies, FE; Drayson, MT; Gregory, WM; Jackson, GH; Morgan, GJ; Owen, RG; Szubert, AJ | 1 |
| Morgan, G | 1 |
| Clark, OA; Djulbegovic, B; Glasmacher, A; Kumar, A; Mhaskar, R; Miladinovic, B; Redzepovic, J; Wheatley, K | 1 |
| Bruscino-Raiola, F; Hewson, I; Syme, D | 1 |
| Freiberger, JJ; Kraft, KH; McGraw, T; Moon, RE; Padilla-Burgos, R; Piantadosi, CA; Stolp, BW; Suliman, HB | 1 |
| Canuto, RA; Carossa, S; Maggiora, M; Martinasso, G; Mozzati, M; Muzio, G; Oraldi, M; Scoletta, M; Zambelli, M | 1 |
| Dispenzieri, A; Gertz, MA; Greipp, PR; Hassoun, H; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, KM; Lust, JA; Mandrekar, SJ; Rajkumar, SV; Reeder, CB; Roy, V; Witzig, TE | 1 |
| Edwards, CM; Edwards, JR; Lwin, ST; Mundy, GR; Yang, X; Zhang, J; Zhuang, J | 1 |
| Locke, FL; Morgan, GJ | 1 |
| Kamoh, AK; Ogle, O | 1 |
| Suzuki, K | 1 |
| McCarthy, PL | 1 |
| Cha, YJ; Lee, YJ | 1 |
| Collet, P; Marotte, H; Nizeica, V | 1 |
| Anderson, K; Berenson, JR; Biermann, JS; Hillner, BE; Kyle, RA; Lipton, A; Yee, GC | 1 |
| Forciniti, S; Galea, E; Tagliaferri, P; Tassone, P; Venuta, S | 1 |
| Cohen, MH; Dagher, R; Griebel, DJ; Ibrahim, A; Martin, A; Pazdur, R; Scher, NS; Sokol, GH; Williams, GA | 1 |
| Culligan, DJ; Gordon, S; Greaves, M; Helfrich, MH; Ralston, SH; Rogers, MJ; Sati, HI; Soutar, RL | 1 |
| Dolan, G; Jones, SG; Lengyel, K; Myers, B | 1 |
| Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M | 1 |
| Croucher, PI; De Hendrik, R; Green, J; Hijzen, A; Lippitt, J; Perry, MJ; Shipman, CM; Van Camp, B; Van Marck, E; Vanderkerken, K | 1 |
| Ashcroft, AJ; Davies, FE; Morgan, GJ | 1 |
| Gimsing, P; Jurlander, J; Nielsen, LB; Salomo, M | 1 |
| Booth, B; Chen, G; Gobburu, JV; Hsieh, Y; Ibrahim, A; Leighton, J; Li, N; Pazdur, R; Rahman, A; Scher, N; Sridhara, R; Vause, D; Williams, G; Wood, R | 1 |
| Arcara, C; Caccamo, N; Di Sano, C; Dieli, F; Fulfaro, F; Gebbia, N; Meraviglia, S; Montesano, C; Poccia, F; Salerno, A; Sireci, G; Valerio, MR | 1 |
| Apffelstaedt, J; Belch, A; Chen, BL; Coleman, RE; Gordon, D; Howell, A; Hussein, MA; Kaminski, M; Mackey, J; Reitsma, DJ; Rosen, LS; Seaman, JJ | 1 |
| Hohneker, J; Lacerna, L | 1 |
| Avcu, F; Nevruz, O; Pekel, A; Sengul, A; Ural, AU; Yalcin, A; Yilmaz, MI; Zerman, M | 1 |
| Khaira, NS; Sekhon, JS; Singh, D | 1 |
| Decker, JL; Henderson, C; Hohneker, JA; Kaplan, BH; Lacerna, L; Orlowski, R; Purdy, MH; Schnell, FM; Vogel, CL; Wood, AJ; Yanagihara, RH | 1 |
| Algur, E; Häfeli, UO; Macklis, RM | 1 |
| Inoue, K; Kawada, K; Minami, H; Okabe, K; Sasaki, T; Sawamura, M; Takashima, S; Watanabe, T; Yagi, Y | 1 |
| Coleman, RE; Glendenning, GA; Radeva, JI; Reed, SD; Schulman, KA | 1 |
| Bertieri, R; Boano, L; Boccadoro, M; Bruno, B; Castella, B; Coscia, M; Fiore, F; Foglietta, M; Mariani, S; Massaia, M; Muraro, M; Nuschak, B; Palumbo, A; Pantaleoni, F; Peola, S | 1 |
| Antonioli, E; Bosi, A; Ficarra, G; Vannucchi, AM | 1 |
| Chou, T | 1 |
| Beilin, J; Ingram, KB; Nguyen, HV | 1 |
| Crowley, J; Durie, BG; Katz, M | 1 |
| Duck, L; Maerevoet, M; Martin, C | 1 |
| Avcu, F; Ural, AU | 4 |
| Corso, A; Ferretti, E; Lazzarino, M | 1 |
| Corradi, D; Manfredi, M; Meleti, M; Merigo, E; Vescovi, P | 1 |
| Broumand, V; Fortin, M; Marx, RE; Sawatari, Y | 1 |
| Fietkau, R; Gundlach, KK; Lenz, JH; Mueller, PC; Schmidt, W; Steiner-Krammer, B | 1 |
| Cull, G; Henley, D; Kaye, J; Walsh, J | 1 |
| Anagnostopoulos, A; Bamia, C; Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Koutsoukou, V; Melakopoulos, I; Moulopoulos, LA; Papadimitriou, C; Terpos, E | 1 |
| Vastag, B | 1 |
| Etayo-Pérez, A; Garatea-Crelgo, J; Martino-Gorbea, R; Pastor-Zuazaga, D; Sebastián-López, C | 1 |
| Baccarani, M; Boni, P; Cangini, D; Cavo, M; Ceccolini, M; Cellini, C; Parente, R; Perrone, G; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E | 1 |
| Bishop, PA; Hay, KD | 1 |
| Dimitrakopoulos, I; Karakasis, D; Magopoulos, C | 1 |
| Elting, LS; Migliorati, CA; Siegel, MA | 1 |
| Anagnostopoulos, A; Bamia, C; Bamias, A; Dimopoulos, MA; Gika, D; Kastritis, E; Melakopoulos, I; Moulopoulos, LA; Terpos, E; Tsionos, K | 1 |
| Bemardeschi, P; Dentico, P; Fiorentini, G; Giustarini, G; Rossi, S; Turano, E | 1 |
| Gregersen, H; Neumann, B | 1 |
| Biasotto, M; Cavalli, F; Chiandussi, S; Cova, MA; Di Lenarda, R; Dore, F | 1 |
| Bergsagel, PL; Carr, AB; Dalton, RJ; Dingli, D; Dispenzieri, A; Fonseca, R; Gertz, MA; Gollbach, KL; Greipp, PR; Hayman, SR; Kademani, D; Keller, EE; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Reeder, CB; Roy, V; Russell, SJ; Stewart, AK; Viozzi, CF; Witzig, TE; Zeldenrust, SR | 1 |
| Baumann, P; Emmerich, B; Meinhardt, G; Schmidmaier, R; Simsek, M | 1 |
| Baumann, A; Czerny, C; Eisenmenger, G; Ewers, R; Hoffmann, M; Moser, D; Pietschmann, P; Wutzl, A | 1 |
| Baulch-Brown, C; Ma, D; Molloy, TJ; Spencer, A; Yeh, SL | 1 |
| Badros, A; Benderson, D; Karakunnel, J; Kathuria, S | 1 |
| McKenna, KE; Morris, TC; Ramadan, KM | 1 |
| Anagnostopoulos, A; Chantry, A; Croucher, PI; Dimopoulos, MA; Heath, DJ; Katodritou, E; Pouli, A; Rahemtulla, A; Terpos, E; Verrou, E; Vervessou, EC; Zervas, K | 1 |
| Baccarani, M; Brioli, A; Cangini, D; Catalano, L; Cavo, M; Ceccolini, M; Cellini, C; D'Arco, A; Di Raimondo, F; Offidani, M; Perrone, G; Ronconi, S; Tacchetti, P; Tosi, P; Tura, S; Zamagni, E | 1 |
| Avanzati, A; Gennari, L; Gozzetti, A; Lauria, F; Martini, G; Nuti, R | 1 |
| Battley, J; Jayathissa, S; Seneviratne, E | 1 |
| Calvo-Villas, JM; Carreter de Granda, E; Govantes Rodríguez, J; Sicilia Guillén, F; Tapia Torres, M | 1 |
| Barnett, JB; de Lemos, ML; Hu, F; Levin, A; Moravan, V; O'Reilly, SE; Taylor, SC | 1 |
| Alati, C; Allegra, A; Alonci, A; Cicciù, M; De Ponte, FS; Musolino, C; Nastro, E; Oteri, G; Quartarone, E | 1 |
| Agurto P, J; Anguita C, T; Laissle C, G; Roa E, I | 1 |
| Bonaninil, M; Corcione, L; Corradi, D; D'Aleo, P; Ferrari, S; Guidotti, R; Manfredi, M; Meleti, M; Merigo, E; Poli, T; Ripasarti, A; Sesenna, E; Vescovi, P; Zanzucchi, E | 1 |
| Agazzi, A; D'Orto, O; Derada Troletti, G; Diego, R; Fontanella, W; Marzano, U; Pagani, D; Pignataro, L | 1 |
| Araújo, SR; Cossolin, GS; Curi, MM; dos Santos, MO; Feher, O; Koga, DH; Zardetto, C | 1 |
| Blasick, TM; Brown, RE; Quiery, AT; Zhang, PL | 1 |
| Anaissie, EJ; Boyette, J; Clarke, BM; Stack, BC; Suen, JY; Vural, E | 1 |
| de Visscher, JG; Schortinghuis, J; Spijkervet, KL; Witjes, MJ | 1 |
| Corso, A; Klersy, C; Lazzarino, M; Mangiacavalli, S; Pica, G; Varettoni, M; Zappasodi, P | 1 |
| Fantini, M; Nicoletti, S; Poggi, B; Possenti, C; Sartori, S; Tamburini, E; Tassinari, D | 1 |
| Barlogie, B; Elici, F; Gokden, N; Kumar, J; Zangari, M | 1 |
| Bodmer, M; Kummer, O; Ramazzina, C; Rätz Bravo, AE; Zysset Aschmann, Y | 1 |
| Amico, P; Bodmer, M; Haschke, M; Krähenbühl, S; Kummer, O; Mayr, M; Mihatsch, MJ | 1 |
| Berenson, JR; Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR; Terpos, E | 1 |
| Briones, DL; Ferres, AJ; Herbozo, PJ; Torrealba, RL | 1 |
| Alpay, N; Ayer, M; Küçükkaya, RD; Mete, O; Nalçaci, M; Yavuz, AS; Yenerel, MN; Yildirim, ND | 1 |
| Kouvaris, C; Mouzopoulos, D; Mouzopoulos, G; Stamatakos, M; Tzurbakis, M | 1 |
| Crawford, B; Gibson, J; Iland, H; Joshua, D; Joy Ho, P; Sanders, J | 1 |
| Avilés, A; Castañeda, C; Cleto, S; Huerta-Guzmán, J; Nambo, MJ; Neri, N | 1 |
| Cho, R; Koizumi, M; Nakaseko, C; Nishimura, M; Ohwada, C; Ozawa, S; Saito, Y; Shimizu, N; Takeuchi, M | 1 |
| Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR | 1 |
| Guthmiller, JM; Humbert, LA; Johnson, GK; Statz, TA | 1 |
| Bonneterre, J; Cortet, B; Facon, T; Maes, JM; Magro, L; Penel, G; Vieillard, MH | 1 |
| Bostan, F; Ozkaynak, C; Timurağaoğlu, A; Tuzuner, S; Undar, L | 1 |
| Botelho, C; Cavaleiro, MV; Cortez, PP; Hussain, NS; Lobato, JV; Maurício, AC; Rodrigues, JM; Santos, JD; Xavier, L | 1 |
| Bertieri, R; Boccarelli, A; Cirulli, T; Coluccia, AM; Coluccia, M; Dammacco, F; Di Pietro, G; Giannini, T; Mangialardi, G; Ribatti, D; Scavelli, C; Vacca, A | 1 |
| Cabezas Macián, A; Gutiérrez Pérez, JL; Infante Cossío, P; Palomino Nicas, J; Pérez Ceballos, JL | 1 |
| Bedogni, A; Bedogni, G; Blandamura, S; Chiarini, L; Ferrari, F; Ferretti, M; Ferronato, G; Lo Muzio, L; Lo Russo, L; Lokmic, Z; Ninfo, V; Nocini, PF; Palumbo, C; Pietrogrande, F; Procopio, O; Ragazzo, M; Saia, G; Tregnaghi, A | 1 |
| McKeage, K; Plosker, GL | 1 |
| Dhillon, S; Lyseng-Williamson, KA | 1 |
| Caruso, PA; Dodson, TB; Raje, NS; Rosenberg, AE | 1 |
| Bilic, S; Copeman, M; Cremers, S; Kennedy, N; Lynch, K; Neeman, T; Ravera, C; Roberts, A; Schran, H; Spencer, A | 1 |
| Avanzati, A; Campagna, MS; De Paola, V; Franci, B; Gennari, L; Gozzetti, A; Lauria, F; Marchini, E; Martini, G; Merlotti, D; Nuti, R; Salvadori, S; Tozzi, M | 1 |
| Andriani, A; Barbarano, L; Bibas, M; Cafro, AM; D'Avanzo, G; Gaglioti, D; Morra, E; Nichelatti, M; Nosari, AM; Riva, F; Taroni, A | 1 |
| Delmas, PD | 1 |
| Aparicio, A; Berenson, J; Gardner, A; Lichtenstein, A; Savage, A; Tu, Y | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Amiot, M; Barillé, S; Bataille, R; Berthaud, P; Collette, M; Derenne, S; Harousseau, JL; Robillard, N | 1 |
| Forciniti, S; Galea, E; Martinelli, V; Morrone, G; Tagliaferri, P; Tassone, P; Turco, MC; Venuta, S | 1 |
| Berenson, JR; Coleman, RE; Dreicer, R; Howell, A; Kuross, SA; Lipton, A; Morley, W; Porter, L; Rosen, LS; Seaman, JJ | 1 |
| Ali, SM; Costa, L; Esteva, FJ; Harvey, H; Hortobagyi, G; Knight, R; Lipton, A; Seaman, J | 1 |
| Hussein, MA; Juturi, JV; Lieberman, I | 1 |
| Barlogie, B; Choi, Y; Epstein, J; Johnson, CL; Pearse, RN; Yaccoby, S | 1 |
51 review(s) available for zoledronic acid and Kahler Disease
| Article | Year |
|---|---|
A systematic review and meta-analysis of interventional studies of bisphosphonates and denosumab in multiple myeloma and future perspectives.
Topics: Clodronic Acid; Denosumab; Diphosphonates; Humans; Multiple Myeloma; Zoledronic Acid | 2022 |
Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents.
Topics: Bone and Bones; Bone Diseases; Cytokines; Humans; Multiple Myeloma; Tumor Microenvironment; Zoledronic Acid | 2023 |
A Patient with a History of Multiple Myeloma Presents for the Evaluation of Oral Lesion and Burning Sensation of the Mouth.
Topics: Face; Humans; Mouth; Multiple Myeloma; Pain; Zoledronic Acid | 2023 |
Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Humans; Multiple Myeloma; Randomized Controlled Trials as Topic; Zoledronic Acid | 2020 |
Controversies in the use of new bone-modifying therapies in multiple myeloma.
Topics: Bone Density Conservation Agents; COVID-19; Denosumab; Diphosphonates; Humans; Hypercalcemia; Multiple Myeloma; Osteolysis; Receptor Activator of Nuclear Factor-kappa B; Renal Insufficiency; Zoledronic Acid | 2021 |
Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Humans; Multiple Myeloma; Plasmacytoma; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2021 |
Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Neoplasms; Osteoclasts; RANK Ligand; Treatment Outcome; Zoledronic Acid | 2018 |
Bisphosphonates in multiple myeloma: an updated network meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Disease-Free Survival; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid | 2017 |
Management of multiple myeloma bone disease: impact of treatment on renal function.
Topics: Bone Density Conservation Agents; Bone Diseases; Disease Management; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Multiple Myeloma; Osteolysis; Practice Guidelines as Topic; Zoledronic Acid | 2018 |
Bisphosphonates for Patients Diagnosed With Multiple Myeloma.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Randomized Controlled Trials as Topic; Review Literature as Topic; Zoledronic Acid | 2018 |
Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Bone Diseases; Bone Morphogenetic Proteins; Bortezomib; Genetic Markers; Humans; Mice; Multiple Myeloma; Osteocytes; Osteogenesis; Osteolysis; Zoledronic Acid | 2018 |
Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Bone Density Conservation Agents; Bone Diseases; Denosumab; Humans; Multiple Myeloma; RANK Ligand; Zoledronic Acid | 2019 |
[Inhibition of RANK ligand to treat bone metastases].
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2013 |
Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
Topics: Breast Neoplasms; Clodronic Acid; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Neoplasm Metastasis; Pamidronate; Prostatic Neoplasms; Zoledronic Acid | 2013 |
Zoledronic acid in the management of bone disease as a consequence of multiple myeloma: a review.
Topics: Antineoplastic Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Drug Monitoring; Humans; Ibandronic Acid; Imidazoles; Multiple Myeloma; Pamidronate; Zoledronic Acid | 2014 |
Treatment of multiple myeloma bone disease: experimental and clinical data.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Quality of Life; Zoledronic Acid | 2015 |
Therapeutic options in the management of myeloma bone disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases; Clinical Trials as Topic; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Zoledronic Acid | 2010 |
Skull base osteomyelitis and bisphosphonate use in multiple myeloma: report of two cases and literature review.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteomyelitis; Retrospective Studies; Skull Base; Tomography, X-Ray Computed; Zoledronic Acid | 2010 |
Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Mice; Multiple Myeloma; Osteolysis; Pamidronate; Risk Factors; Spinal Cord Compression; Zoledronic Acid | 2011 |
Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma?
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Breast Neoplasms; Clodronic Acid; Diphosphonates; Drug Evaluation, Preclinical; Female; Humans; Imidazoles; Male; Mice; Multiple Myeloma; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Research Design; Risk Factors; Treatment Outcome; Zoledronic Acid | 2011 |
The backbone of progress--preclinical studies and innovations with zoledronic acid.
Topics: Animals; Apoptosis; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Imidazoles; Mice; Multiple Myeloma; Neovascularization, Pathologic; Osteoclasts; Zoledronic Acid | 2011 |
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.
Topics: Acute-Phase Reaction; Bone Diseases; Diphosphonates; Endothelial Cells; Humans; Imidazoles; Multiple Myeloma; Osteoclasts; Osteocytes; Osteonecrosis; Pamidronate; Practice Guidelines as Topic; Zoledronic Acid | 2011 |
Supportive therapy in multiple myeloma.
Topics: Anemia; Blood Transfusion; Bone Diseases; Calcitonin; Clodronic Acid; Diphosphonates; Erythropoietin; Fractures, Bone; Hematinics; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteoporosis; Pamidronate; Recombinant Proteins; Renal Insufficiency; Zoledronic Acid | 2011 |
Zoledronic acid: multiplicity of use across the cancer continuum.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Neoplasms; Zoledronic Acid | 2011 |
Antitumor effects of bisphosphonates: from the laboratory to the clinic.
Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Breast Neoplasms; Cell Adhesion Molecules; Diphosphonates; Female; Humans; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Zoledronic Acid | 2011 |
Denosumab: benefits of RANK ligand inhibition in cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Multiple Myeloma; RANK Ligand; Zoledronic Acid | 2011 |
The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Clinical Trials as Topic; Clodronic Acid; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Multiple Myeloma; Osteolysis; Practice Guidelines as Topic; Zoledronic Acid | 2012 |
[Multiple myeloma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Denosumab; Diphosphonates; Humans; Imidazoles; Melphalan; Multiple Myeloma; Peripheral Nervous System Diseases; Prednisolone; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Zoledronic Acid | 2012 |
Bisphosphonates in multiple myeloma: a network meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2012 |
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; Humans; Imidazoles; In Situ Hybridization, Fluorescence; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Proteinuria; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Time Factors; Translocation, Genetic; Treatment Outcome; Zoledronic Acid | 2012 |
Current therapeutic strategy for multiple myeloma.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Creatinine; Cyclophosphamide; Denosumab; Dexamethasone; Diphosphonates; Doxorubicin; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulins; Kidney; Lenalidomide; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Melphalan; Molecular Targeted Therapy; Multiple Myeloma; Neoplasms, Second Primary; Precision Medicine; Prednisolone; Pyrazines; Quality of Life; Recurrence; Remission Induction; Survival Rate; Thalidomide; Zoledronic Acid | 2013 |
Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diphosphonates; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Pyrazines; Thalidomide; Transplantation, Autologous; Zoledronic Acid | 2013 |
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Topics: Adenocarcinoma; Biomarkers; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Osteoblasts; Osteoclasts; Osteolysis; Osteoporosis; Pain; Pamidronate; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Safety; Zoledronic Acid | 2002 |
Advances in the biology and treatment of myeloma bone disease.
Topics: Bone Resorption; Boronic Acids; Bortezomib; Carrier Proteins; Clinical Trials as Topic; Cytokines; Diphosphonates; Endothelial Growth Factors; Glycoproteins; Humans; Imidazoles; Immunoglobulin Fc Fragments; Intercellular Signaling Peptides and Proteins; Lymphokines; Membrane Glycoproteins; Multiple Myeloma; Osteoprotegerin; Pamidronate; Pyrazines; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Zoledronic Acid | 2002 |
Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Osteoporosis; Randomized Controlled Trials as Topic; Zoledronic Acid | 2003 |
Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.
Topics: Antineoplastic Agents; Bone and Bones; Bone Density; Bone Neoplasms; Chemokines; Clinical Trials as Topic; Clodronic Acid; Cytokines; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteolysis; Patient Selection; Treatment Outcome; Zoledronic Acid | 2003 |
Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors.
Topics: Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Humans; Imidazoles; Lung Neoplasms; Male; Multiple Myeloma; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2003 |
Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease.
Topics: Adjuvants, Immunologic; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Life Tables; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Survival Analysis; Thalidomide; Treatment Outcome; Zoledronic Acid | 2003 |
[Multiple myeloma--recent advances in diagnosis and treatment].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy; Diphosphonates; Dose-Response Relationship, Drug; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Multiple Myeloma; Neoplasm Staging; Pamidronate; Protease Inhibitors; Pyrazines; Thalidomide; Zoledronic Acid | 2005 |
Zoledronic acid exerts its antitumor effect in multiple myeloma interfering with the bone marrow microenvironment.
Topics: Animals; Bone Marrow; Bone Marrow Cells; Cell Proliferation; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Osteoclasts; Plasma Cells; Signal Transduction; Stromal Cells; Zoledronic Acid | 2005 |
Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Dental Care for Chronically Ill; Diphosphonates; Humans; Imidazoles; Jaw; Mandibular Diseases; Multiple Myeloma; Osteonecrosis; Pamidronate; Practice Guidelines as Topic; Time Factors; Zoledronic Acid | 2006 |
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Minnesota; Multiple Myeloma; Osteoporosis; Pamidronate; Practice Guidelines as Topic; Zoledronic Acid | 2006 |
Scleritis complicating zoledronic acid infusion.
Topics: Aged; Anti-Inflammatory Agents; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Multiple Myeloma; Pamidronate; Radiography; Scleritis; Zoledronic Acid | 2006 |
[Zoledronate-associated end stage renal failure and hypocalcaemia].
Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Biopsy; Bone Density Conservation Agents; Calcium; Creatinine; Diphosphonates; Disease Progression; Female; Follow-Up Studies; Humans; Hypocalcemia; Imidazoles; Kidney Failure, Chronic; Kidney Tubules; Middle Aged; Multiple Myeloma; Pamidronate; Renal Dialysis; Risk Factors; Switzerland; Time Factors; Vitamin D; Zoledronic Acid | 2007 |
Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma.
Topics: Biomarkers; Bone and Bones; Bone Neoplasms; Diphosphonates; Disease Progression; Humans; Imidazoles; Multiple Myeloma; Osteolysis; Predictive Value of Tests; Risk Factors; Survival Rate; Zoledronic Acid | 2007 |
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Lung Neoplasms; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Quality-Adjusted Life Years; Zoledronic Acid | 2008 |
Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Zoledronic Acid | 2008 |
Clinical research update: zoledronate.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Mice; Multiple Myeloma; Rats; Zoledronic Acid | 1997 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
Advances in the biology and treatment of myeloma bone disease.
Topics: Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Zoledronic Acid | 2001 |
Multiple myeloma: present and future.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Oxides; Pamidronate; Thalidomide; Zoledronic Acid | 2002 |
47 trial(s) available for zoledronic acid and Kahler Disease
| Article | Year |
|---|---|
Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study-Asian Subgroup Analysis.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Double-Blind Method; Female; Humans; Male; Middle Aged; Multiple Myeloma; Treatment Outcome; Zoledronic Acid | 2020 |
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study.
Topics: Aged; Denosumab; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Progression-Free Survival; Transplantation, Autologous; Zoledronic Acid | 2021 |
Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Disease Progression; Female; Humans; Interleukin-2; Italy; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Remission Induction; Time Factors; Treatment Outcome; Zoledronic Acid | 2020 |
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Double-Blind Method; Female; Fractures, Spontaneous; Humans; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Risk Factors; Spinal Cord Compression; Time Factors; Treatment Outcome; Zoledronic Acid | 2018 |
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in the United States of America.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Cost of Illness; Cost-Benefit Analysis; Denosumab; Diphosphonates; Female; Health Expenditures; Humans; Imidazoles; Male; Models, Economic; Multiple Myeloma; Quality-Adjusted Life Years; Survival Analysis; United States; Zoledronic Acid | 2018 |
Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clodronic Acid; Consolidation Chemotherapy; Female; Hematopoietic Stem Cell Transplantation; Humans; Longitudinal Studies; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Quality of Life; Remission Induction; Self Report; Surveys and Questionnaires; Thalidomide; Transplantation, Autologous; Young Adult; Zoledronic Acid | 2018 |
Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?
Topics: Age Factors; Aged; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Collagen Type I; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Peptides; Radionuclide Imaging; Zoledronic Acid | 2013 |
Prospective observational study of treatment pattern, effectiveness and safety of zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone metastases from solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Prospective Studies; Zoledronic Acid | 2013 |
The impact of response on bone-directed therapy in patients with multiple myeloma.
Topics: Adult; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Remission Induction; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Zoledronic Acid | 2013 |
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Denosumab; Diphosphonates; Disease Progression; Double-Blind Method; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasms; Pain; Treatment Outcome; Zoledronic Acid | 2014 |
Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer.
Topics: Adult; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Prospective Studies; Radioimmunoassay; Zoledronic Acid | 2014 |
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Drug Administration Schedule; England; Female; Follow-Up Studies; Humans; Imidazoles; Incidence; Male; Middle Aged; Multiple Myeloma; Osteolysis; Zoledronic Acid | 2014 |
A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events.
Topics: Aged; Anabolic Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Female; Fractures, Spontaneous; Humans; Hypertension; Imidazoles; Intercellular Signaling Peptides and Proteins; Male; Maximum Tolerated Dose; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Osteolysis; Recurrence; Spinal Cord Compression; Zoledronic Acid | 2014 |
Zoledronic Acid may reduce intraoperative bleeding in spinal tumors: a prospective cohort study.
Topics: Adult; Aged; Blood Loss, Surgical; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Spinal Neoplasms; Zoledronic Acid | 2015 |
The role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.
Topics: Antibodies, Monoclonal, Humanized; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Hypercalcemia; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasms; Proportional Hazards Models; Zoledronic Acid | 2015 |
Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.
Topics: Adult; Aged; Bone Diseases; Diphosphonates; Disease-Free Survival; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Survival Rate; Zoledronic Acid | 2015 |
Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Diseases; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Osteolysis; Peptides; Zoledronic Acid | 2016 |
Evaluating results from the multiple myeloma patient subset treated with denosumab or zoledronic acid in a randomized phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Female; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Transplantation, Autologous; Treatment Outcome; Zoledronic Acid | 2016 |
Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Prostatic Neoplasms; Sample Size; Spinal Cord Compression; Spinal Fractures; Zoledronic Acid | 2017 |
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Survival Analysis; Zoledronic Acid | 2008 |
[Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].
Topics: Adult; Aged; Analgesics; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Colorectal Neoplasms; Creatinine; Diphosphonates; Double-Blind Method; Female; Fever; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Pain, Intractable; Pamidronate; Peptides; Prospective Studies; Vomiting; Zoledronic Acid | 2008 |
Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma.
Topics: Adult; Aged; Blood Cells; Bone Density Conservation Agents; Bone Marrow Cells; Cell Culture Techniques; Diphosphonates; Female; Humans; Imidazoles; Immunotherapy, Adoptive; Interleukin-2; Killer Cells, Lymphokine-Activated; Lymphocyte Activation; Lymphocyte Count; Lymphocyte Subsets; Male; Middle Aged; Multiple Myeloma; Pilot Projects; Receptors, Antigen, T-Cell, gamma-delta; Treatment Outcome; Zoledronic Acid | 2009 |
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Research Design; Treatment Outcome; United Kingdom; Zoledronic Acid | 2010 |
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; International Agencies; Male; Middle Aged; Multiple Myeloma; Neoplasms; RANK Ligand; Survival Rate; Treatment Outcome; Young Adult; Zoledronic Acid | 2011 |
Safety and efficacy of zoledronic acid in multiple myeloma.
Topics: Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Humans; Imidazoles; Incidence; Male; Multiple Myeloma; Osteonecrosis; Prognosis; Risk Assessment; Safety Management; Severity of Illness Index; Survival Analysis; Thromboembolism; Zoledronic Acid | 2011 |
Safety and efficacy of zoledronic acid in multiple myeloma.
Topics: Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Multiple Myeloma; Osteonecrosis; Prognosis; Risk Assessment; Safety Management; Survival Analysis; Thromboembolism; Treatment Outcome; Zoledronic Acid | 2011 |
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; United Kingdom; Zoledronic Acid | 2011 |
Multiple myeloma vs. breast cancer patients with bisphosphonates-related osteonecrosis of the jaws: a comparative analysis of response to treatment and predictors of outcome.
Topics: Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Forecasting; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Pain Measurement; Proportional Hazards Models; Prospective Studies; Remission Induction; Treatment Outcome; Wound Healing; Zoledronic Acid | 2012 |
Lower dose dexamethasone/thalidomide and zoledronic acid every 3 weeks in previously untreated multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Models, Biological; Multiple Myeloma; Thalidomide; Treatment Outcome; Zoledronic Acid | 2012 |
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Induction Chemotherapy; Male; Middle Aged; Multiple Myeloma; Thalidomide; Zoledronic Acid | 2012 |
What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics.
Topics: Aged; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Combined Modality Therapy; Debridement; Diphosphonates; Female; Follow-Up Studies; Gingiva; Humans; Hyperbaric Oxygenation; Imidazoles; Male; Multiple Myeloma; Osteoporosis; Pain Management; Pamidronate; Prospective Studies; Quality of Life; Treatment Outcome; Wound Healing; Zoledronic Acid | 2012 |
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imidazoles; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Survival Rate; Thalidomide; Zoledronic Acid | 2013 |
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Kidney; Male; Multiple Myeloma; Neoplasm Metastasis; Placebos; Prostatic Neoplasms; Time Factors; United States; United States Food and Drug Administration; Zoledronic Acid | 2003 |
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
Topics: Bone Diseases; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Pamidronate; Zoledronic Acid | 2003 |
Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.
Topics: Aged; Arthralgia; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Creatinine; Diphosphonates; Fatigue; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Nausea; Pain; Pain Measurement; Prospective Studies; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid | 2004 |
A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
Topics: Adult; Aged; Breast Neoplasms; Calcium; Diphosphonates; Dose-Response Relationship, Drug; Female; Head and Neck Neoplasms; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Treatment Outcome; Zoledronic Acid | 2005 |
First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
Topics: Adult; Aged; Alkaline Phosphatase; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Remodeling; Bone Resorption; Collagen Type I; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Osteocalcin; Pain; Peptides; Thalidomide; Treatment Outcome; Zoledronic Acid | 2006 |
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Risk; Time Factors; Zoledronic Acid | 2006 |
Low-dose thalidomide plus monthly high-dose oral dexamethasone (Thali-Dexa): results, prognostic factors and side effects in eight patients previously treated with multiple myeloma.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Sedimentation; Dexamethasone; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pamidronate; Prognosis; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome; Zoledronic Acid | 2003 |
Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Retrospective Studies; Thalidomide; Zoledronic Acid | 2006 |
Zoledronic acid treatment at home: safety data from an observational prospective trial.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Creatinine; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Home Care Services; Humans; Imidazoles; Karnofsky Performance Status; Male; Middle Aged; Multiple Myeloma; Observation; Prospective Studies; Prostatic Neoplasms; Survival Analysis; Time Factors; Zoledronic Acid | 2007 |
Is there a case for the early use of bisphosphonates in smouldering myeloma and MGUS? (Bisphosphonates in SMM & MGUS).
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Osteoporosis; Paraproteinemias; Zoledronic Acid | 2007 |
Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Zoledronic Acid | 2007 |
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Creatinine; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Injections, Intravenous; Male; Multiple Myeloma; Osteoclasts; Osteolysis; Pamidronate; Peptides; Retrospective Studies; Risk Assessment; Survival Rate; Treatment Outcome; Zoledronic Acid | 2007 |
Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Diphosphonates; Female; Humans; Imidazoles; Kidney; Male; Middle Aged; Multiple Myeloma; Prednisolone; Thalidomide; Zoledronic Acid | 2008 |
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Collagen; Collagen Type I; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Multiple Myeloma; Pain Measurement; Pamidronate; Peptides; Zoledronic Acid | 2001 |
Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.
Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Osteolysis; Pamidronate; Time Factors; Zoledronic Acid | 2001 |
174 other study(ies) available for zoledronic acid and Kahler Disease
| Article | Year |
|---|---|
Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells.
Topics: Aminopyridines; Aniline Compounds; Antineoplastic Agents; Apoptosis; Catalytic Domain; Cell Survival; Crystallography, X-Ray; Diphosphonates; Drug Design; Extracellular Signal-Regulated MAP Kinases; Geranyltranstransferase; Hemiterpenes; Humans; Models, Molecular; Multiple Myeloma; Organophosphorus Compounds; Phosphorylation; Protein Conformation; Small Molecule Libraries; Stereoisomerism; Structure-Activity Relationship; Tumor Cells, Cultured | 2012 |
Unraveling the Prenylation-Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors.
Topics: Apoptosis; Catalytic Domain; Cell Proliferation; Enzyme Inhibitors; Geranylgeranyl-Diphosphate Geranylgeranyltransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Multiple Myeloma; Protein Prenylation; Pyrimidines; rap1 GTP-Binding Proteins | 2018 |
Evaluation of denosumab in adult oncology patients for the prevention of skeletal related events across a large academic health system.
Topics: Adult; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Calcium; Denosumab; Diphosphonates; Humans; Multiple Myeloma; Retrospective Studies; Vitamin D; Zoledronic Acid | 2023 |
Pamidronate versus zoledronic acid for the treatment of multiple myeloma-related hypercalcemia.
Topics: Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Pamidronate; Zoledronic Acid | 2022 |
Prognosis of metastatic bone cancer and myeloma patients and long-term risk of medication-related osteonecrosis of the jaw (MRONJ): some critical points.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Humans; Incidence; Multiple Myeloma; Osteonecrosis; Prognosis; Retrospective Studies; Zoledronic Acid | 2022 |
Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status.
Topics: Bone Marrow; Hepatitis A Virus Cellular Receptor 2; Humans; Multiple Myeloma; Neoplasm Recurrence, Local; Programmed Cell Death 1 Receptor; Receptors, Antigen, T-Cell; T-Lymphocytes; Tumor Microenvironment; Zoledronic Acid | 2022 |
Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma.
Topics: Adolescent; Adult; Aged; Bone and Bones; Bone Neoplasms; Cohort Studies; Diphosphonates; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Young Adult; Zoledronic Acid | 2020 |
Life-threatening hypophosphataemia secondary to zoledronic acid implementation in a middle-age patient who presented with advanced osteolysis in the course of multiple myeloma.
Topics: Bone Density Conservation Agents; Humans; Hypophosphatemia; Male; Middle Aged; Multiple Myeloma; Osteolysis; Zoledronic Acid | 2020 |
Multiple myeloma and chemical maxillary osteonecrosis. Can both occur simultaneously?
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Humans; Multiple Myeloma; Retrospective Studies; Zoledronic Acid | 2020 |
Mesenchymal stromal cells administration for osteonecrosis of the jaw caused by bisphosphonate: report of two cases.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Female; Humans; Male; Mesenchymal Stem Cell Transplantation; Multiple Myeloma; Zoledronic Acid | 2020 |
Successful percutaneous treatment of bone tumors using microwave ablation in combination with Zoledronic acid infused PMMA cementoplasty.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Cementoplasty; Female; Humans; Male; Microwaves; Multiple Myeloma; Pelvis; Polymethyl Methacrylate; Radiofrequency Therapy; Spine; Zoledronic Acid | 2020 |
Safety and efficacy of bone-modifying agents among multiple myeloma patients: A retrospective cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Hypocalcemia; Middle Aged; Multiple Myeloma; Osteonecrosis; Retrospective Studies; Young Adult; Zoledronic Acid | 2022 |
Medication-related osteonecrosis of the jaw in a patient with multiple myeloma: an unusual case with tumor in the surgical specimen.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Female; Humans; Multiple Myeloma; Pain; Zoledronic Acid | 2022 |
Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies; Bone Density; Bone Morphogenetic Proteins; Cell Line, Tumor; Diphosphonates; Fractures, Bone; Genetic Markers; Humans; Imidazoles; Mice; Multiple Myeloma; Osteocytes; Osteogenesis; Tumor Cells, Cultured; Zoledronic Acid | 2017 |
Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Cytochrome P-450 CYP2C8; Humans; Multiple Myeloma; Polymorphism, Single Nucleotide; PPAR gamma; Risk Factors; Zoledronic Acid | 2017 |
Removal of a sequestrum by a patient with medication-related osteonecrosis of the jaw.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Multiple Myeloma; Self Care; Zoledronic Acid | 2017 |
Evidence of novel miR-34a-based therapeutic approaches for multiple myeloma treatment.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Humans; MicroRNAs; Multiple Myeloma; Naphthols; Zoledronic Acid | 2017 |
Denosumab for myeloma bone disease: ready for prime time?
Topics: Bone Diseases; Denosumab; Double-Blind Method; Humans; Multiple Myeloma; Zoledronic Acid | 2018 |
Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diphosphonates; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Humans; Imidazoles; Lymphocytes; Male; MicroRNAs; Middle Aged; Monocytes; Multiple Myeloma; Osteoclasts; Osteolysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Zoledronic Acid | 2018 |
Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma.
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Inflammation; Male; Middle Aged; Multiple Myeloma; Orbital Diseases; Zoledronic Acid | 2019 |
Radiographic bone loss and the risk of medication-related osteonecrosis of the jaw (MRONJ) in multiple myeloma patients-A retrospective case control study.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Case-Control Studies; Diphosphonates; Female; Humans; Male; Middle Aged; Multiple Myeloma; Radiography, Panoramic; Retrospective Studies; Risk Factors; Zoledronic Acid | 2018 |
Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models.
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Neoplasms, Experimental; Osteolysis; Transforming Growth Factor beta; Xenograft Model Antitumor Assays; Zoledronic Acid | 2019 |
Use of Bisphosphonates in Elderly Patients With Newly Diagnosed Multiple Myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Medicare; Multiple Myeloma; Pamidronate; Practice Guidelines as Topic; Retrospective Studies; SEER Program; Treatment Outcome; United States; Zoledronic Acid | 2019 |
A cost-effectiveness analysis of denosumab for the prevention of skeletal-related events in patients with multiple myeloma in four European countries: Austria, Belgium, Greece, and Italy.
Topics: Bone Density Conservation Agents; Bone Diseases; Cost-Benefit Analysis; Denosumab; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Health Expenditures; Humans; Markov Chains; Models, Economic; Multiple Myeloma; Quality-Adjusted Life Years; Survival Analysis; Zoledronic Acid | 2019 |
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
Topics: Administration, Intravenous; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Combined Modality Therapy; Diphosphonates; Drug Therapy, Combination; Fractures, Bone; Humans; Imidazoles; International Cooperation; Magnetic Resonance Imaging; Medical Oncology; Multiple Myeloma; Osteonecrosis; Outcome Assessment, Health Care; Pamidronate; Positron-Emission Tomography; Practice Guidelines as Topic; Radiotherapy; Tomography, X-Ray Computed; Zoledronic Acid | 2013 |
Cell therapy in bisphosphonate-related osteonecrosis of the jaw.
Topics: Aged; Autografts; Biocompatible Materials; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Marrow Transplantation; Bone Matrix; Bone Regeneration; Bone Substitutes; Calcium Phosphates; Debridement; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Injections, Intravenous; Mandibular Diseases; Multiple Myeloma; Platelet-Rich Plasma; Stem Cell Transplantation; Zoledronic Acid | 2013 |
Hemorrhagic bullous colitis in a patient with multiple myeloma.
Topics: Aged; Amyloidosis; Antifibrinolytic Agents; Blister; Bone Density Conservation Agents; Colitis, Ischemic; Diphosphonates; Female; Gastrointestinal Hemorrhage; Humans; Imidazoles; Multiple Myeloma; Radiography; Sigmoidoscopy; Tranexamic Acid; Zoledronic Acid | 2013 |
Management of bisphosphonate-related osteonecrosis of the jaw with a platelet-rich fibrin membrane: technical report.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Blood Platelets; Diphosphonates; Fibrin; Humans; Imidazoles; Male; Membranes, Artificial; Multiple Myeloma; Pamidronate; Zoledronic Acid | 2014 |
Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Diphosphonates; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Hydroxamic Acids; Imidazoles; Indoles; Male; Mevalonic Acid; Mice; Mice, Nude; Models, Biological; Multiple Myeloma; p38 Mitogen-Activated Protein Kinases; Panobinostat; Prostatic Neoplasms; Reactive Oxygen Species; Signal Transduction; Xenograft Model Antitumor Assays; Zoledronic Acid | 2013 |
Hyperammonemic encephalopathy in multiple myeloma.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Boronic Acids; Bortezomib; Brain; Brain Edema; Coma; Cyclophosphamide; Dexamethasone; Diphosphonates; Fatal Outcome; Humans; Hyperammonemia; Imidazoles; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteolysis; Pyrazines; Tomography, X-Ray Computed; Zoledronic Acid | 2014 |
Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Follow-Up Studies; Gingival Crevicular Fluid; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplasms; Osteoprotegerin; Prognosis; RANK Ligand; Survival Rate; Zoledronic Acid | 2014 |
[Effect of the administration of zoledronic acid on life expectancy in patients with multiple myeloma with or without renal impairment].
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Life Expectancy; Male; Middle Aged; Multiple Myeloma; Renal Insufficiency; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2014 |
Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma.
Topics: Aged; Bone Density Conservation Agents; Bone Resorption; Cohort Studies; Comparative Effectiveness Research; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pamidronate; Propensity Score; Proportional Hazards Models; Registries; Survival Rate; Veterans; Zoledronic Acid | 2015 |
Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
Topics: Antineoplastic Combined Chemotherapy Protocols; Back Pain; Biopsy; Bone Density Conservation Agents; Bone Marrow; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Hematopoietic Stem Cell Transplantation; Humans; Imidazoles; Immunoglobulin G; Immunoglobulin lambda-Chains; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Pyrazines; Referral and Consultation; Thalidomide; Translocation, Genetic; Transplantation, Autologous; Zoledronic Acid | 2014 |
Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Collagen Type I; Cytokines; Diphosphonates; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Osteonecrosis; Pamidronate; Peptides; Prognosis; Zoledronic Acid | 2014 |
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid | 2015 |
Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Multiple Myeloma; Tomography, X-Ray Computed; Vitamin D Deficiency; Zoledronic Acid | 2014 |
Markers of bone metabolism in multiple myeloma patients switched from zoledronic acid to denosumab.
Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Calcium; Cell Differentiation; Collagen Type I; Denosumab; Diphosphonates; Drug Substitution; Female; Humans; Imidazoles; Isoenzymes; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Osteoblasts; Osteocalcin; Osteogenesis; Peptides; RANK Ligand; Retrospective Studies; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2014 |
NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.
Topics: Animals; Bone and Bones; Bone Diseases; Bone Marrow; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Multiple Myeloma; Neoplasm Transplantation; Oligopeptides; Tumor Cells, Cultured; Zoledronic Acid | 2015 |
Isopentenyl pyrophosphate secreted from Zoledronate-stimulated myeloma cells, activates the chemotaxis of γδT cells.
Topics: Cell Line, Tumor; Chemotaxis, Leukocyte; Culture Media, Conditioned; Diphosphonates; Hemiterpenes; Humans; Imidazoles; Multiple Myeloma; Organophosphorus Compounds; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid | 2015 |
[Management of bone disease in myeloma patients: zoledronic acid or denosumab?].
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Denosumab; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Zoledronic Acid | 2015 |
Not all ST-segment changes are myocardial injury: hypercalcaemia-induced ST-segment elevation.
Topics: Aged, 80 and over; Bone Density Conservation Agents; Brugada Syndrome; Cardiac Conduction System Disease; Diagnosis, Differential; Diphosphonates; Diuretics; Echocardiography; Electrocardiography; Follow-Up Studies; Furosemide; Humans; Hypercalcemia; Imidazoles; Male; Multiple Myeloma; Myocardial Ischemia; Point-of-Care Testing; Treatment Outcome; Zoledronic Acid | 2015 |
[Clinical significance of serum bone metabolic markers in diagnosis and monitoring of myeloma bone disease].
Topics: Acid Phosphatase; Biomarkers; Collagen Type I; Diphosphonates; Humans; Imidazoles; Isoenzymes; Multiple Myeloma; Osteoporosis; Procollagen; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2015 |
Two diagnoses from bone marrow biopsy: multiple myeloma and Paget's disease of bone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Bortezomib; Dexamethasone; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Osteitis Deformans; Treatment Outcome; Zoledronic Acid | 2016 |
Severe clavicular disease in multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clavicle; Diphosphonates; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Multiple Myeloma; Shoulder Fractures; Stem Cell Transplantation; Tomography, X-Ray Computed; Transplantation, Autologous; Treatment Outcome; Vertebroplasty; Zoledronic Acid | 2016 |
Autofluorescence as indicator for detecting the surgical margins of medication-related osteonecrosis of the jaws.
Topics: Aged; Aged, 80 and over; Bicuspid; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Breast Neoplasms; Cementoplasty; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Laser Therapy; Lasers, Solid-State; Lung Neoplasms; Male; Margins of Excision; Middle Aged; Multiple Myeloma; Optical Imaging; Postoperative Complications; Tooth Extraction; Zoledronic Acid | 2016 |
Expansion of Th
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Diphosphonates; Humans; Imidazoles; Immunologic Factors; Lenalidomide; Multiple Myeloma; T-Lymphocytes; Th1 Cells; Thalidomide; Zoledronic Acid | 2017 |
CYR61/CCN1 stimulates proliferation and differentiation of osteoblasts in vitro and contributes to bone remodeling in vivo in myeloma bone disease.
Topics: Adult; Aged; Animals; Bone Diseases; Bone Marrow Cells; Bone Remodeling; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cysteine-Rich Protein 61; Diphosphonates; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; Mice; Middle Aged; Multiple Myeloma; Neoplasm Transplantation; Osteoblasts; Wnt Signaling Pathway; Zoledronic Acid | 2017 |
Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients.
Topics: Adult; Aged; Bone Density Conservation Agents; Diphosphonates; Disease-Free Survival; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Quality of Life; Zoledronic Acid | 2017 |
Consequence of therapy discontinuation in bisphosphonate-associated osteonecrosis of the jaws.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents, Local; Bone Density Conservation Agents; Bone Neoplasms; Chlorhexidine; Debridement; Diphosphonates; Female; Humans; Hydrogen Peroxide; Imidazoles; Maxillary Diseases; Middle Aged; Mouthwashes; Multiple Myeloma; Oroantral Fistula; Osteonecrosis; Tooth Extraction; Zoledronic Acid | 2009 |
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dental Prophylaxis; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pyrazines; Retrospective Studies; Thalidomide; Young Adult; Zoledronic Acid | 2009 |
Radiology quiz case. Osteonecrosis of the jaw: aminobisphosphonate epidemic.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Disease Outbreaks; Humans; Image Processing, Computer-Assisted; Imidazoles; Male; Mandibular Diseases; Multiple Myeloma; Osteonecrosis; Radiography, Panoramic; Reoperation; Tomography, Spiral Computed; Zoledronic Acid | 2008 |
[Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma].
Topics: Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw; Multiple Myeloma; Oral Hygiene; Osteonecrosis; Pamidronate; Risk Factors; Zoledronic Acid | 2009 |
Effects of platelet-derived growth factor, vitamin D and parathyroid hormone on osteoblasts derived from cancer patients on chronic bisphosphonate therapy.
Topics: Aged; Antigens, Differentiation; Bone Density Conservation Agents; Bone Regeneration; Breast Neoplasms; Calcitriol; Cell Differentiation; Cells, Cultured; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Osteoblasts; Parathyroid Hormone; Platelet-Derived Growth Factor; Vitamin D; Zoledronic Acid | 2009 |
Recurrent low-energy femoral shaft fractures and osteonecrosis of the jaw in a case of multiple myeloma treated with bisphosphonates.
Topics: Bone Density Conservation Agents; Cross Infection; Diphosphonates; Escherichia coli Infections; Fatal Outcome; Femoral Fractures; Fractures, Spontaneous; Humans; Imidazoles; Injections, Intravenous; Male; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Osteopetrosis; Recurrence; Zoledronic Acid | 2009 |
Bisphosphonate-related osteonecrosis of the skull base.
Topics: Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Neurosurgical Procedures; Osteonecrosis; Skull Base; Tomography, X-Ray Computed; Zoledronic Acid | 2009 |
Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Dexamethasone; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Middle Aged; Multiple Myeloma; Necrosis; Osteoclasts; Osteonecrosis; Thalidomide; Zoledronic Acid | 2009 |
The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Models, Animal; Female; Humans; Imidazoles; Mice; Mice, SCID; Multiple Myeloma; Protein Prenylation; Transplantation, Heterologous; Zoledronic Acid | 2010 |
[Case of acute kidney injury related to intravenous zoledronic acid in a patient with multiple myeloma].
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases; Dexamethasone; Diphosphonates; Doxorubicin; Humans; Imidazoles; Injections, Intravenous; Male; Multiple Myeloma; Renal Dialysis; Treatment Outcome; Vincristine; Zoledronic Acid | 2009 |
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Greece; Humans; Ibandronic Acid; Imidazoles; Incidence; Jaw Diseases; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2009 |
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Jaw Diseases; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Retrospective Studies; Spinal Cord Compression; Time Factors; Treatment Outcome; Zoledronic Acid | 2009 |
Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Adhesion; Cell Movement; Cell Proliferation; Diphosphonates; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Macrophages; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; NF-kappa B; Phosphorylation; Pyrazines; Vascular Endothelial Growth Factor Receptor-2; Zoledronic Acid | 2010 |
IgE-type multiple myeloma with the late development of IgA2 kappa and plasma cell leukaemia.
Topics: Aged; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Diphosphonates; Drug Therapy, Combination; Fatal Outcome; Female; Humans; Imidazoles; Immunoglobulin A; Immunoglobulin E; Immunoglobulin kappa-Chains; Leukemia, Plasma Cell; Melphalan; Multiple Myeloma; Myeloma Proteins; Neoplasms, Second Primary; Prednisone; Zoledronic Acid | 2010 |
Bisphosphonate-induced osteonecrosis of the jaw 32 months after interruption of zoledronate in a patient with multiple myeloma.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Maxillary Diseases; Multiple Myeloma; Oroantral Fistula; Osteonecrosis; Zoledronic Acid | 2010 |
Prognostic variables for survival and skeletal complications in patients with multiple myeloma osteolytic bone disease.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Diseases; Clinical Trials, Phase III as Topic; Diphosphonates; Double-Blind Method; Female; Humans; Imidazoles; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Osteolysis; Pamidronate; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid | 2010 |
Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Survival Rate; Treatment Outcome; Zoledronic Acid | 2010 |
Effect of withdrawal of zoledronic acid treatment on bone remodelling markers in multiple myeloma.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Diphosphonates; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Zoledronic Acid | 2010 |
Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells.
Topics: Apoptosis; Biosynthetic Pathways; Cell Line, Tumor; Diphosphonates; Dose-Response Relationship, Drug; Endoplasmic Reticulum; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Immunoblotting; Immunoglobulin lambda-Chains; Immunoglobulin Light Chains; Lovastatin; Multiple Myeloma; Prenylation; rab1 GTP-Binding Proteins; Reverse Transcriptase Polymerase Chain Reaction; Terpenes; Tunicamycin; Unfolded Protein Response; Zoledronic Acid | 2011 |
Mechanisms behind the anti-tumour effects of zoledronic acid use in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Zoledronic Acid | 2010 |
The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.
Topics: Aged; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Proliferation; Diphosphonates; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Oxides; Polymerase Chain Reaction; Pyrazines; Zoledronic Acid | 2011 |
Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Prognosis; Retrospective Studies; Risk Factors; Zoledronic Acid | 2011 |
Zoledronic acid in myeloma: MRC Myeloma IX.
Topics: Administration, Oral; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Drug Administration Schedule; Humans; Imidazoles; Infusions, Intravenous; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2010 |
Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Gene Frequency; Genetic Predisposition to Disease; Geranyltranstransferase; Humans; Imidazoles; Italy; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Pharmacogenetics; Polymorphism, Single Nucleotide; Retrospective Studies; White People; Zoledronic Acid | 2011 |
Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws.
Topics: Bone Density Conservation Agents; Breast Neoplasms; Case-Control Studies; Chi-Square Distribution; Diphosphonates; Female; Haplotypes; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Odds Ratio; Osteonecrosis; Polymorphism, Single Nucleotide; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2011 |
Development of multiple myeloma in a case of longstanding ankylosing spondylitis: more than a coincidence?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Diphosphonates; Etoricoxib; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pyridines; Sacroiliitis; Spondylitis, Ankylosing; Sulfones; Thalidomide; Zoledronic Acid | 2011 |
Zoledronic acid: a framework of emerging anticancer evidence throughout the cancer continuum.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Zoledronic Acid | 2011 |
[Case report; a case of acute kidney injury due to intravenous zoledronic acid hydrate, improved with bortezomib plus dexamethazone therapy in a patient with multiple myeloma].
Topics: Acute Kidney Injury; Adult; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Injections, Intravenous; Male; Multiple Myeloma; Pyrazines; Zoledronic Acid | 2011 |
Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw.
Topics: Adult; Aged; Aryl Hydrocarbon Hydroxylases; Bone Density Conservation Agents; Cohort Studies; Collagen Type I; Collagen Type I, alpha 1 Chain; Cytochrome P-450 CYP2C8; Diphosphonates; Female; Gene Frequency; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Matrix Metalloproteinase 2; Middle Aged; Multiple Myeloma; Osteonecrosis; Osteopontin; Osteoprotegerin; Pamidronate; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Receptor Activator of Nuclear Factor-kappa B; Risk Factors; Smoking; Time Factors; Tumor Necrosis Factor-alpha; Zoledronic Acid | 2011 |
Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes.
Topics: Animals; Antineoplastic Agents; Bone Density Conservation Agents; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Delivery Systems; Humans; Imidazoles; Liposomes; Male; Mice; Mice, Nude; Multiple Myeloma; Neovascularization, Pathologic; Prostate; Prostatic Neoplasms; Zoledronic Acid | 2011 |
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Gene Frequency; Genetic Predisposition to Disease; Humans; Imidazoles; Jaw Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Polymorphism, Single Nucleotide; PPAR gamma; Zoledronic Acid | 2011 |
Ras inhibition and the survival benefit favoring zoledronic acid compared with denosumab in patients with multiple myeloma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biopsy; Bone Neoplasms; Denosumab; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Neoplasm Metastasis; Neoplasms; Protein Processing, Post-Translational; Randomized Controlled Trials as Topic; RANK Ligand; ras Proteins; Treatment Outcome; Zoledronic Acid | 2011 |
Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells.
Topics: Cell Communication; Cell Culture Techniques; Cell Movement; Cytotoxicity, Immunologic; Diphosphonates; Humans; Imidazoles; Interleukin-2; Multiple Myeloma; Osteoclasts; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid | 2011 |
Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.
Topics: Aged; Bone Density Conservation Agents; Bone Diseases; Bone Diseases, Metabolic; Comorbidity; Diphosphonates; Drug Administration Schedule; Female; Fractures, Spontaneous; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Proportional Hazards Models; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid | 2011 |
Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vγ9Vδ2 T cells, αβ CD8+ T cells, regulatory T cells, and dendritic cells.
Topics: B7-1 Antigen; Bone Density Conservation Agents; CD8-Positive T-Lymphocytes; Cell Communication; Cell Proliferation; Dendritic Cells; Diphosphonates; Gene Expression Regulation; Hemiterpenes; Humans; Imidazoles; Lymphocyte Activation; Mevalonic Acid; Monocytes; Multiple Myeloma; Organophosphorus Compounds; Programmed Cell Death 1 Ligand 2 Protein; Receptors, Antigen, T-Cell, alpha-beta; Receptors, Antigen, T-Cell, gamma-delta; Zoledronic Acid | 2011 |
Zoledronic acid for all patients with newly diagnosed multiple myeloma?
Topics: Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Female; Fractures, Spontaneous; Humans; Imidazoles; Male; Multiple Myeloma; Zoledronic Acid | 2011 |
Further analyses of the Myeloma IX Study.
Topics: Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Osteonecrosis; Thrombosis; Zoledronic Acid | 2011 |
Association of laser phototherapy with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws in cancer patients: a preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Lasers, Semiconductor; Low-Level Light Therapy; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Platelet-Rich Plasma; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Treatment Outcome; Zoledronic Acid | 2012 |
Bisphosphonate-associated osteonecrosis of the jaw: a six-year history of a case.
Topics: Bone Density Conservation Agents; Debridement; Diphosphonates; Disease Progression; Follow-Up Studies; Humans; Imidazoles; Immunoglobulin kappa-Chains; Male; Mandibular Diseases; Mandibular Neoplasms; Middle Aged; Multiple Myeloma; Osteonecrosis; Recurrence; Zoledronic Acid | 2011 |
The Medical Research Council Myeloma IX Trial: new clinical insights on the anticancer effects of zoledronic acid in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2012 |
Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from the United Kingdom healthcare system perspective.
Topics: Bone Density Conservation Agents; Clodronic Acid; Cost-Benefit Analysis; Delivery of Health Care; Diphosphonates; Humans; Imidazoles; Models, Economic; Multiple Myeloma; Quality-Adjusted Life Years; Survival Analysis; United Kingdom; Zoledronic Acid | 2012 |
Bisphosphonate therapy in multiple myeloma in preventing vertebral collapses: preliminary report.
Topics: Adult; Aged; Bone Diseases; Bone Resorption; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteogenesis; Pain Measurement; Positron-Emission Tomography; Quality of Life; Retrospective Studies; Spine; Treatment Outcome; Zoledronic Acid | 2012 |
Persistency with zoledronic acid is associated with clinical benefit in patients with multiple myeloma.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Databases, Factual; Diphosphonates; Drug Utilization; Female; Fractures, Spontaneous; Humans; Imidazoles; Incidence; Infusions, Intravenous; International Classification of Diseases; Male; Medication Adherence; Middle Aged; Multiple Myeloma; Osteolysis; Retrospective Studies; Treatment Outcome; United States; Zoledronic Acid | 2012 |
Myeloma: diagnosis complications and supportive care.
Topics: Amyloidosis; Anemia; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Boronic Acids; Bortezomib; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Pyrazines; Quality of Life; Renal Insufficiency; Thrombosis; Zoledronic Acid | 2012 |
Radical surgical treatment of bisphosphonate related osteonecrosis of the jaw.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Maxillary Diseases; Maxillary Osteotomy; Middle Aged; Multiple Myeloma; Pamidronate; Peptides; Surgical Flaps; Tooth Extraction; Zoledronic Acid | 2012 |
Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Case-Control Studies; Cell Proliferation; Cytokines; Diphosphonates; Endothelial Cells; Female; Gingival Crevicular Fluid; Humans; Hydroxymethylglutaryl CoA Reductases; Imidazoles; Injections, Intravenous; Interleukin-6; Male; Middle Aged; Mouth Mucosa; Multiple Myeloma; Osteoclasts; Osteoprotegerin; RANK Ligand; Statistics, Nonparametric; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2013 |
Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.
Topics: Animals; Bone and Bones; CD11b Antigen; Cell Differentiation; Cell Line, Tumor; Diphosphonates; Female; Humans; Imidazoles; Mice; Multiple Myeloma; Myeloid Cells; Osteoclasts; Prenylation; Tumor Microenvironment; Zoledronic Acid | 2012 |
Updates in the treatment of multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; B-Cell Maturation Antigen; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Disease Management; Humans; Imidazoles; Killer Cells, Natural; Multiple Myeloma; Proteasome Inhibitors; Quality of Life; Recurrence; Survival Analysis; T-Lymphocytes; Zoledronic Acid | 2012 |
Bisphosphonate-related osteonecrosis of the jaws--a case report.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Comorbidity; Diphosphonates; Female; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Zoledronic Acid | 2012 |
Risk factors for renal impairment in patients with solid tumors or multiple myeloma treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Contraindications; Creatinine; Diphosphonates; Dose-Response Relationship, Drug; Drug Monitoring; Female; Hospitals, Teaching; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Neoplasms; Practice Guidelines as Topic; Renal Insufficiency; Republic of Korea; Retrospective Studies; Risk Factors; Zoledronic Acid | 2013 |
Bortezomib induced a phrenic palsy in a multiple myeloma patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bortezomib; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Diagnosis, Differential; Diphosphonates; gamma-Aminobutyric Acid; Humans; Imidazoles; Male; Melphalan; Multiple Myeloma; Nerve Compression Syndromes; Neuralgia; Phrenic Nerve; Prednisone; Pregabalin; Protease Inhibitors; Pyrazines; Respiratory Paralysis; Zoledronic Acid | 2013 |
FDA approves ZOMETA for treatment of cancer-related bone complications.
Topics: Bone Neoplasms; Diphosphonates; Drug Approval; Humans; Imidazoles; Infusions, Intravenous; Multiple Myeloma; United States; United States Food and Drug Administration; Zoledronic Acid | 2002 |
American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
Topics: Clodronic Acid; Diphosphonates; Drug Monitoring; Humans; Imidazoles; Multiple Myeloma; Osteolysis; Pamidronate; Zoledronic Acid | 2002 |
The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Cell Division; Dexamethasone; Diphosphonates; Drug Synergism; Flow Cytometry; Humans; Imidazoles; Interleukin-6; Membrane Glycoproteins; Multiple Myeloma; Proteoglycans; Receptors, Interleukin-6; Syndecans; Time Factors; Tumor Cells, Cultured; Zoledronic Acid | 2002 |
U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bone Neoplasms; Cystitis; Diphosphonates; Drug Approval; Gastrointestinal Neoplasms; Hematuria; Hemorrhage; Humans; Ifosfamide; Imatinib Mesylate; Imidazoles; Mesna; Multiple Myeloma; Orphan Drug Production; Piperazines; Protective Agents; Pyrimidines; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Zoledronic Acid | 2002 |
Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Diphosphonates; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pamidronate; Plasma Cells; Protein Prenylation; Tumor Cells, Cultured; Zoledronic Acid | 2002 |
Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions.
Topics: Aged; Creatinine; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Immunosuppressive Agents; Male; Multiple Myeloma; Thalidomide; Zoledronic Acid | 2002 |
Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
Topics: Animals; Bone Density; Diphosphonates; Disease-Free Survival; Imidazoles; Mice; Mice, Inbred C57BL; Multiple Myeloma; Neovascularization, Pathologic; Zoledronic Acid | 2003 |
How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics.
Topics: Alendronate; Alkyl and Aryl Transferases; Apoptosis; Blotting, Western; Diphosphonates; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Geranyltranstransferase; Humans; Imidazoles; Linear Models; Multiple Myeloma; Polymerase Chain Reaction; Treatment Failure; Tumor Cells, Cultured; Zoledronic Acid | 2003 |
Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo.
Topics: Diphosphonates; Humans; Imidazoles; Lymphoma, Non-Hodgkin; Multiple Myeloma; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Zoledronic Acid | 2003 |
The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide.
Topics: Antineoplastic Agents; Apoptosis; Calcium; Cell Cycle; Cell Division; Dexamethasone; Diphosphonates; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Egtazic Acid; Enzyme Inhibitors; Humans; Imidazoles; Leukemia, Plasma Cell; Multiple Myeloma; Neoplasm Proteins; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Protein Kinase C; Staurosporine; Thalidomide; Tumor Cells, Cultured; Zoledronic Acid | 2003 |
Treatment strategies for myeloma bone disease.
Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Magnetic Resonance Imaging; Middle Aged; Multiple Myeloma; Orthopedic Procedures; Pamidronate; Zoledronic Acid | 2003 |
Symptomatic hypocalcaemia after treatment with zoledronic acid in a patient with multiple myeloma.
Topics: Calcium; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Middle Aged; Multiple Myeloma; Zoledronic Acid | 2004 |
Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines.
Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; Diphosphonates; Drug Screening Assays, Antitumor; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Radiation Tolerance; Radiotherapy Dosage; Zoledronic Acid | 2005 |
Economic evaluation of zoledronic acid versus pamidronate for the prevention of skeletal-related events in metastatic breast cancer and multiple myeloma.
Topics: Ambulatory Care; Bone Neoplasms; Breast Neoplasms; Costs and Cost Analysis; Diphosphonates; Female; Hospitalization; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2005 |
Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.
Topics: Antineoplastic Agents; Cell Communication; Cell Division; Cells, Cultured; Diphosphonates; Humans; Imidazoles; Immunologic Factors; Immunologic Memory; In Vitro Techniques; Interleukin-2; Multiple Myeloma; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocyte Subsets; Zoledronic Acid | 2005 |
Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma.
Topics: Aged; Diphosphonates; Humans; Imidazoles; Jaw; Male; Multiple Myeloma; Osteonecrosis; Zoledronic Acid | 2005 |
[Rapid drug information].
Topics: Adverse Drug Reaction Reporting Systems; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Information Services; Germany; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Osteoporosis; Pamidronate; Risk Assessment; Zoledronic Acid | 2005 |
Profound hypocalcaemia after zoledronic acid treatment.
Topics: Aged; Aged, 80 and over; Diphosphonates; Female; Humans; Hypocalcemia; Imidazoles; Multiple Myeloma; Zoledronic Acid | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Breast Neoplasms; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Pamidronate; Risk Factors; Zoledronic Acid | 2005 |
Osteonecrosis of the jaw and bisphosphonates.
Topics: Breast Neoplasms; Dental Care; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Multiple Myeloma; Osteonecrosis; Risk Factors; Zoledronic Acid | 2005 |
Evolving therapeutic role of bisphosphonates in multiple myeloma.
Topics: Apoptosis; Cell Proliferation; Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Zoledronic Acid | 2005 |
Zoledronic acid sensitizes tumor cells to radiation: in response to Algur et al. (Int J Radiat Oncol Biol Phys 2005;61:535-542).
Topics: Animals; Cell Cycle; Cell Line, Tumor; Combined Modality Therapy; Diphosphonates; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Proto-Oncogene Proteins p21(ras); Radiation Tolerance; Radiation-Sensitizing Agents; Zoledronic Acid | 2005 |
Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): a four-case report.
Topics: Aged; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Curettage; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Recurrence; Zoledronic Acid | 2005 |
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.
Topics: Abscess; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Dental Caries; Dexamethasone; Diphosphonates; Drug Interactions; Female; Humans; Hyperostosis; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Osteopetrosis; Osteoporosis; Pamidronate; Periodontitis; Prostatic Neoplasms; Risk Factors; Tooth Extraction; Zoledronic Acid | 2005 |
Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Diphosphonates; Female; Humans; Ibandronic Acid; Imidazoles; Mandibular Diseases; Maxillary Diseases; Multiple Myeloma; Osteomyelitis; Osteonecrosis; Zoledronic Acid | 2005 |
Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma.
Topics: Acute Kidney Injury; Aged; Bone Density Conservation Agents; Calcitriol; Calcium Carbonate; Diphosphonates; Fatal Outcome; Female; Humans; Hypocalcemia; Imidazoles; Injections, Intravenous; Magnesium Deficiency; Male; Middle Aged; Multiple Myeloma; Pamidronate; Zoledronic Acid | 2005 |
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Greece; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prospective Studies; Prostatic Neoplasms; Risk Factors; Time Factors; Treatment Failure; Zoledronic Acid | 2005 |
Consumer groups look to improve adverse event reporting systems.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Bone Density Conservation Agents; Consumer Behavior; Diphosphonates; Drug Approval; Humans; Imidazoles; Multiple Myeloma; Osteonecrosis; Pamidronate; Product Surveillance, Postmarketing; United States; United States Food and Drug Administration; Zoledronic Acid | 2005 |
Osteonecrosis of the jaws and bisphosphonates. Report of three cases.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Hypercalcemia; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Tooth Extraction; Zoledronic Acid | 2006 |
Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications.
Topics: Adenocarcinoma; Aged, 80 and over; Bone Density Conservation Agents; Carcinoma; Diabetes Mellitus, Type 2; Diphosphonates; Female; Follow-Up Studies; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Patient Care Planning; Tooth Extraction; Zoledronic Acid | 2006 |
Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Retrospective Studies; Tooth Extraction; Zoledronic Acid | 2006 |
Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: possible mechanisms?
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Diphosphonates; Docetaxel; Drug Synergism; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2006 |
[Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis].
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Pamidronate; Zoledronic Acid | 2006 |
Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Radiography, Panoramic; Radionuclide Imaging; Retrospective Studies; Technetium Tc 99m Medronate; Tomography, X-Ray Computed; Zoledronic Acid | 2006 |
Synergistic antimyeloma effects of zoledronate and simvastatin.
Topics: Apoptosis; Bone Density Conservation Agents; Bone Marrow; Cell Adhesion; Cell Line, Tumor; Diphosphonates; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Multiple Myeloma; Simvastatin; Stromal Cells; Zoledronic Acid | 2006 |
Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
Topics: Adult; Aged; Biopsy; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Follow-Up Studies; Histiocytosis, Langerhans-Cell; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Magnetic Resonance Imaging; Male; Mandible; Mandibular Diseases; Maxilla; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Radiography, Panoramic; Radionuclide Imaging; Retrospective Studies; Risk Factors; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2006 |
Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Imidazoles; Indoles; Mevalonic Acid; Multiple Myeloma; Piperidines; Pyridines; Structure-Activity Relationship; Zoledronic Acid | 2007 |
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Squamous Cell; Clarithromycin; Dexamethasone; Diphosphonates; Glomerulonephritis; Humans; Idarubicin; Imidazoles; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Pamidronate; Protein Synthesis Inhibitors; Pyrazines; Skin Neoplasms; Thalidomide; Zoledronic Acid | 2006 |
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
Topics: Acid Phosphatase; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Bone Remodeling; Boronic Acids; Bortezomib; Case-Control Studies; Collagen Type I; Diphosphonates; Female; Humans; Imidazoles; Intercellular Signaling Peptides and Proteins; Isoenzymes; Male; Middle Aged; Multiple Myeloma; Osteocalcin; Osteoprotegerin; Peptides; Protease Inhibitors; Pyrazines; RANK Ligand; Recurrence; Statistics, Nonparametric; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2006 |
The effect of zoledronic acid on serum osteoprotegerin in early stage multiple myeloma.
Topics: Diphosphonates; Humans; Imidazoles; Multiple Myeloma; Osteoprotegerin; Zoledronic Acid | 2006 |
Jaw osteonecrosis associated with bisphosphonates.
Topics: Aged; Diphosphonates; Fatal Outcome; Humans; Imidazoles; Male; Maxilla; Multiple Myeloma; Osteonecrosis; Radiography; Zoledronic Acid | 2006 |
[Osteonecrosis of the jaw in patients with multiple myeloma during and after treatment with zoledronic acid].
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Risk Factors; Zoledronic Acid | 2006 |
Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Creatinine; Diphosphonates; Drug Administration Schedule; Drug Costs; Female; Health Care Costs; Humans; Imidazoles; Infusions, Intravenous; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Pamidronate; Prevalence; Registries; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2006 |
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.
Topics: Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw Diseases; Male; Mandible; Maxilla; Middle Aged; Multiple Myeloma; Necrosis; Osteonecrosis; Pamidronate; Tomography, X-Ray Computed; Zoledronic Acid | 2007 |
[Osteonecrosis associated with the use of biphosphonates: Case report].
Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Multiple Myeloma; Osteonecrosis; Pamidronate; Zoledronic Acid | 2006 |
Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
Topics: Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Antifungal Agents; Bone Density Conservation Agents; Bone Neoplasms; Chlorhexidine; Curettage; Diphosphonates; Female; Humans; Hydrogen Peroxide; Imidazoles; Jaw Diseases; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Mouthwashes; Multiple Myeloma; Osteonecrosis; Osteoporosis; Pamidronate; Radiography; Time Factors; Zoledronic Acid | 2006 |
Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Zoledronic Acid | 2007 |
Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: Report of 3 cases.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Mandibular Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Platelet-Rich Plasma; Tooth Extraction; Zoledronic Acid | 2007 |
Morphoproteomic expression of H-ras (p21ras) correlates with serum monoclonal immunoglobulin reduction in multiple myeloma patients following pamidronate treatment.
Topics: Alkyl and Aryl Transferases; Biomarkers; Cell Proliferation; Diphosphonates; Farnesyltranstransferase; Humans; Imidazoles; Immunoglobulin A; Immunoglobulin G; Immunohistochemistry; Multiple Myeloma; Pamidronate; Pennsylvania; Proto-Oncogene Proteins p21(ras); Zoledronic Acid | 2007 |
Bisphosphonates and jaw osteonecrosis: the UAMS experience.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Bone Density Conservation Agents; Curettage; Dental Care; Diphosphonates; Female; Humans; Hyperbaric Oxygenation; Imidazoles; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Retrospective Studies; Time Factors; Treatment Outcome; Zoledronic Acid | 2007 |
[Osteonecrosis of the jawbone as a side effect of intravenous treatment with bisphosphonates].
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Injections, Intravenous; Male; Mandibular Diseases; Multiple Myeloma; Oral Hygiene; Osteonecrosis; Zoledronic Acid | 2007 |
A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.
Topics: Aged; Diphosphonates; Drug Administration Schedule; Drug Evaluation; Female; Humans; Imidazoles; Incidence; Jaw Diseases; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Retrospective Studies; Risk Factors; Zoledronic Acid | 2007 |
Potential effect of zoledronate therapy in heavy proteinuria.
Topics: Biopsy; Bone Density Conservation Agents; Diphosphonates; Female; Glucocorticoids; Humans; Hypercalcemia; Imidazoles; Middle Aged; Multiple Myeloma; Prednisone; Proteinuria; Zoledronic Acid | 2007 |
Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Glomerulosclerosis, Focal Segmental; Humans; Imidazoles; Kidney; Male; Multiple Myeloma; Nephrotic Syndrome; Time Factors; Treatment Outcome; Zoledronic Acid | 2007 |
Therapeutic role of bisphosphonate and radiation combination in the management of myeloma bone disease.
Topics: Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Cell Cycle; Combined Modality Therapy; Diphosphonates; Disease Progression; Humans; Imidazoles; Multiple Myeloma; Orthopedics; Radiopharmaceuticals; Zoledronic Acid | 2007 |
Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws.
Topics: Aged; Aged, 80 and over; Alveolar Process; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Mandibular Diseases; Maxillary Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Radiography; Severity of Illness Index; Zoledronic Acid | 2007 |
Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide; Vasculitis, Leukocytoclastic, Cutaneous; Zoledronic Acid | 2007 |
Spontaneous bilateral subcapital hip fracture due to multiple myeloma: an 18-month follow-up.
Topics: Adult; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Femoral Neck Fractures; Fracture Fixation, Internal; Fractures, Spontaneous; Humans; Imidazoles; Male; Multiple Myeloma; Radiography; Zoledronic Acid | 2007 |
Zoledronate has an antitumor effect and induces actin rearrangement in dexamethasone-resistant myeloma cells.
Topics: Actins; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Dexamethasone; Diphosphonates; Diterpenes; Drug Resistance, Neoplasm; Humans; Imidazoles; Multiple Myeloma; Protein Prenylation; rap1 GTP-Binding Proteins; rhoA GTP-Binding Protein; Zoledronic Acid | 2007 |
Intravenous bisphosphonate-associated osteonecrosis of the jaw.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Jaw Diseases; Male; Mandibular Fractures; Multiple Myeloma; Osteonecrosis; Radiography; Zoledronic Acid | 2007 |
Thirteen cases of jaw osteonecrosis in patients on bisphosphonate therapy.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw; Male; Middle Aged; Multiple Myeloma; Orthognathic Surgical Procedures; Osteonecrosis; Osteoporosis; Pamidronate; Prospective Studies; Zoledronic Acid | 2008 |
Improvement of zoledronic-acid-induced jaw osteonecrosis with bortezomib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Doxorubicin; Female; Humans; Imidazoles; Mandibular Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Protease Inhibitors; Pyrazines; Tooth Extraction; Transplantation, Autologous; Vincristine; Zoledronic Acid | 2007 |
Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Humans; Imidazoles; Male; Mandibular Diseases; Multiple Myeloma; Osteonecrosis; Radiography, Panoramic; Zoledronic Acid | 2008 |
Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma.
Topics: Adult; Aged; Base Sequence; Blotting, Western; Culture Media, Conditioned; Diphosphonates; DNA Primers; Enzyme-Linked Immunosorbent Assay; Female; Humans; Imidazoles; Lovastatin; Male; Middle Aged; Multiple Myeloma; Neovascularization, Pathologic; Phenotype; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2007 |
Bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma.
Topics: Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Imidazoles; Male; Mandibular Diseases; Middle Aged; Multiple Myeloma; Osteonecrosis; Tooth Extraction; Wound Healing; Zoledronic Acid | 2008 |
Bisphosphonate-associated jawbone osteonecrosis: a correlation between imaging techniques and histopathology.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Jaw; Jaw Diseases; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Tomography, Spiral Computed; Tooth Extraction; Water; Zoledronic Acid | 2008 |
Case records of the Massachusetts General Hospital. Case 9-2008. A 65-year-old woman with a nonhealing ulcer of the jaw.
Topics: Aged; Diagnosis, Differential; Diphosphonates; Female; Gingiva; Gingival Diseases; Humans; Imidazoles; Mandible; Mandibular Diseases; Multiple Myeloma; Osteonecrosis; Precipitating Factors; Radiography; Tooth Extraction; Ulcer; Zoledronic Acid | 2008 |
The effects of zoledronic acid on serum lipids in multiple myeloma patients.
Topics: Aged; Aged, 80 and over; Atherosclerosis; Bone Density Conservation Agents; Cholesterol, HDL; Collagen; Diphosphonates; Female; Humans; Imidazoles; Lipids; Male; Middle Aged; Multiple Myeloma; Treatment Outcome; Zoledronic Acid | 2008 |
Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Female; Humans; Imidazoles; Male; Mandible; Maxilla; Middle Aged; Multiple Myeloma; Necrosis; Zoledronic Acid | 2008 |
Zoledronate.
Topics: Bone Neoplasms; Diphosphonates; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteitis Deformans; Osteoporosis; Zoledronic Acid | 1996 |
In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates.
Topics: Antineoplastic Agents; Apoptosis; Calcium; Cell Death; Cell Division; Cell Survival; Chelating Agents; Diphosphonates; Drug Screening Assays, Antitumor; Humans; Imidazoles; Interleukin-6; Multiple Myeloma; Pamidronate; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Zoledronic Acid | 1998 |
Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Bone Resorption; Cell Division; Cell Survival; Diphosphonates; Humans; Imidazoles; Interleukin-1; Interleukin-6; Matrix Metalloproteinase 1; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Multiple Myeloma; Pamidronate; Tumor Cells, Cultured; Zoledronic Acid | 1999 |
Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines.
Topics: Apoptosis; Cell Division; Dexamethasone; Diphosphonates; Drug Synergism; Flow Cytometry; Humans; Imidazoles; Multiple Myeloma; Tumor Cells, Cultured; Zoledronic Acid | 2000 |
Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.
Topics: Animals; Bone Marrow Cells; Bone Transplantation; Cell Division; Diphosphonates; Humans; Imidazoles; Mice; Mice, SCID; Multiple Myeloma; Osteoclasts; Pamidronate; Transplantation, Heterologous; Zoledronic Acid | 2002 |